

Retinoblastoma, the visible CNS tumor: a review

Helen Dimaras¹⁻⁵ & Timothy W. Corson^{6-9,*}

¹
Department of Ophthalmology and Vision Sciences, Faculty of Medicine, University of Toronto, Toronto, ON, M5S 1A8, Canada

²
Division of Clinical Public Health, Dalla Lana School of Public Health, University of Toronto, Toronto, ON, M5S 1A8, Canada

³
Department of Ophthalmology and Vision Sciences, The Hospital for Sick Children, Toronto, ON, M5G 1X8, Canada

⁴
Child Health Evaluative Sciences Program, SickKids Research Institute, Toronto, ON, M5G 1X8, Canada

⁵
Department of Human Pathology, College of Health Sciences, University of Nairobi, Nairobi, Kenya

⁶
Eugene and Marilyn Glick Eye Institute, Department of Ophthalmology, Indiana University School of Medicine, Indianapolis, IN, 46202, USA

⁷
Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, IN, 46202, USA

⁸
Department of Pharmacology & Toxicology, Indiana University School of Medicine, Indianapolis, IN, 46202, USA

⁹
Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN, 46202, USA

Running head: Retinoblastoma, the visible CNS tumor: a review

Handling Editor: Royce Mohan (Special Issue on “Rare Diseases of the Eye”)

Keywords: pediatric cancer; optical coherence tomography; *MYCN*; cancer genetics; pineoblastoma; neuroimaging

Support: Work in the laboratory of TWC is supported by NIH/NEI R01EY025641, St. Baldrick’s Foundation, the Retina Research Foundation, and an unrestricted grant from Research to Prevent Blindness, Inc. Work in the laboratory of HD is supported by the Canadian Institutes for Health Research and Brandan’s Eye Research Foundation.

*Correspondence to: Timothy W. Corson, PhD, Eugene and Marilyn Glick Eye Institute, Department of Ophthalmology, Indiana University School of Medicine, 1160 West Michigan Street, Indianapolis, IN, 46202, 4620rson@iu.edu

This is the author's manuscript of the article published in final edited form as:

ABSTRACT

The pediatric ocular cancer retinoblastoma is the only central nervous system tumor readily observed without specialized equipment: it can be seen by, and in, the naked eye. This accessibility enables unique imaging modalities. Here, we review this cancer for a neuroscience audience, highlighting these clinical and research imaging options, including fundus imaging, optical coherence tomography, ultrasound, and magnetic resonance imaging. We also discuss the subtype of retinoblastoma driven by the *MYCN* oncogene more commonly associated with neuroblastoma, and consider trilateral retinoblastoma, in which an intracranial tumor arises along with ocular tumors in patients with germline *RB1* gene mutations. Retinoblastoma research and clinical care can offer insights applicable to CNS malignancies, and also benefit from approaches developed elsewhere in the CNS.

SIGNIFICANCE

Retinoblastoma is the most common eye cancer in children. It arises in the developing retina, part of the central nervous system (CNS). Thus, retinoblastoma is a CNS cancer viewable from outside. Retinoblastoma is usually caused by mutations in the *RB1* gene, but can also be caused by amplification of the neuroblastoma oncogene *MYCN*. Rarely, *RB1* gene mutations cause a tumor within the brain as well as eye tumors. Retinoblastoma can be imaged by multiple means, including visually through the eye, by ultrasound, magnetic resonance, and optical coherence tomography. Together, these features make retinoblastoma a unique case study amongst CNS tumors.

INTRODUCTION

The pediatric retinal tumor retinoblastoma is the most common eye cancer in children. It is unique amongst CNS tumors as it is visible through the eye without requiring invasive imaging. This provides an unparalleled opportunity to image tumors as they develop or respond to treatment. Moreover, retinoblastoma provides intriguing insights into nervous system disease in its trilateral and *MYCN*-driven forms.

In this review, we introduce retinoblastoma with a focus on these features. In the first part of the review, we describe the clinical, molecular and histological features of this tumor in the context of its treatment and prognosis. In the second section of the review, we focus on innovations in the imaging of retinoblastoma to highlight what this pediatric ocular cancer tells us about CNS malignancy. We follow this with a discussion of the aforementioned trilateral and *MYCN*-driven forms of retinoblastoma, with the goal of highlighting what retinoblastoma research can gain from studies of other CNS malignancies, and vice versa.

RETINOBLASTOMA OVERVIEW

Clinical vignette. A mother in urban Canada is taking photographs of her child, when she notices a strange white reflex in the child's eye (Fig. 1a). Unsure what it is, later that night she types "white eye in baby" into an Internet search engine. A list of results pops up, alerting her that a white pupil could be a sign of cancer. She immediately seeks attention at the nearest hospital, where the child is diagnosed with retinoblastoma.

1
2
3 Similarly, one evening a mother in rural India notices a white reflex in the eye of her
4 child. Her baby does not seem bothered by it, so she does not worry about it too much.
5
6 Later that month a community health worker arrives to check on the family. The mother
7
8 asks about the odd white reflection in her baby's eye. The health worker has just been
9
10 trained on a new app that helps in the diagnosis of eye conditions. Using her
11
12 smartphone, she takes a flash photo of the child's eye, and uses the app's database of
13
14 eye conditions to compare her photograph. She realizes the photo she took looks
15
16 similar to the database photo of retinoblastoma, so she refers the family to hospital.
17
18
19
20
21

22 **Clinical features.** These hypothetical cases illustrate typical presentations of
23
24 retinoblastoma. The incidence of retinoblastoma is constant worldwide at 1 in every
25
26 16,000 live births (Dimaras et al. 2015; Dimaras et al. 2012). As such, countries with
27
28 higher birth rates and populations observe the highest number of cases. The most
29
30 common first signs of retinoblastoma are leukocoria, a white reflex visible through the
31
32 pupil (Fig. 1a), and strabismus, misaligned eyes. Awareness of these early signs of eye
33
34 cancer is crucial to good outcomes for affected children. However, where awareness of
35
36 these signs is low, and access to healthcare is challenging, retinoblastoma is often
37
38 diagnosed late. In this case, the most common sign at presentation may be proptosis,
39
40 where tumor causes the eye to bulge from the orbit. Retinoblastoma can affect one or
41
42 both eyes, and sometimes also the pineal, parasellar or suprasellar regions (trilateral
43
44 retinoblastoma, discussed below).
45
46
47
48
49
50

51 Detection of retinoblastoma by lay people is possible because retinoblastoma is a
52
53 visible tumor with distinct features. Several awareness efforts aim to improve public
54
55 knowledge of the early visible signs of retinoblastoma. These include low-tech
56
57
58
59
60

1
2
3 innovations, such as including images of leukocoria in Maternal Child Health booklets
4
5 (Ministry of Health Kenya 2010) provided to mothers shortly after childbirth, to alert
6
7 them of the signs of retinoblastoma. High-tech innovations include concepts like the
8
9 Portable Eye Examination Kit (Peek), a smartphone application that allows users to
10
11 recognize and detect eye conditions, including retinoblastoma (Bastawrous 2016;
12
13 Bastawrous et al. 2015; Lodhia et al. 2016; Morjaria et al. 2017).
14
15
16
17

18 Medical diagnosis of retinoblastoma is based on the clinical features of the tumors
19
20 visible in the eye upon dilation of the pupil (Dimaras et al. 2012) (Fig. 1b). This differs
21
22 from diagnosis of other cancers, where histological confirmation via biopsy is usually
23
24 required. Biopsy of retinoblastoma is not recommended, as it can induce seeding and
25
26 extraocular spread along the needle tract (Karcioglu 2002).
27
28
29

30 Retinoblastoma is often highly calcified (Fig. 1c) (Bullock et al. 1977). Calcification is
31
32 visible to the naked eye, and can also be detected by ultrasound or MRI (Rodjan et al.
33
34 2015) (see below). Calcification in retinoblastoma is 'dystrophic' (Eagle 2013), that is, it
35
36 occurs in response to tissue damage or necrosis. It is more often observed in tumors of
37
38 older children and advanced retinoblastoma (Levy et al. 2011).
39
40
41
42

43 Retinoma, the benign precursor of retinoblastoma, also displays calcification, along
44
45 with several distinct clinical features; it is described clinically as a grey, translucent
46
47 mass, often with chorioretinal atrophy and variation in the retinal pigment epithelium
48
49 (Dimaras et al. 2009; Dimaras et al. 2008; Gallie et al. 1982b). Retinoma is rare, but can
50
51 be sometimes observed in parents of children with retinoblastoma (Dimaras et al. 2008;
52
53
54
55
56
57
58
59
60

1
2
3 Gallie et al. 1982a). Its rare occurrence suggests that most retinomas undergo
4
5 malignant transformation to retinoblastoma.
6
7

8
9 Growing retinoblastoma tumors produce seeds that detach and adhere below the
10 retina (subretinal seeds) or float into the vitreous (vitreous seeds). The appearance of
11 seeds has been described as fine dust, spheres, or clouds, each with a progressively
12 worse prognosis, respectively (Francis et al. 2015; Francis et al. 2016; Munier 2014).
13
14 Large tumors can lift and detach the retina, and cause significant inflammation and
15 necrosis, sometimes leading to phthisis bulbi (shrinkage of the eye) (Gallie et al. 1982b;
16
17 Kashyap et al. 2011).
18
19

20
21 Tumor can spread beyond the eye by surpassing retinal boundaries, such as
22 Bruch's membrane, to invade the choroid and reach the blood supply. Another common
23 route for tumor dissemination is via the optic nerve to reach the brain and cerebrospinal
24 fluid (CSF) (Mallipatna et al. 2017).
25
26

27
28 **Staging.** The features of retinoblastoma at presentation provide data to accurately
29 classify the disease in each eye, and consequently direct treatment. During the era
30 when retinoblastoma was primarily treated by radiation, the Reese-Ellsworth
31 Classification (Reese and Ellsworth 1963) system was used, separating tumor classes
32 by their predicted response to radiation treatment. As systemic chemotherapy began to
33 replace radiation as the most common form of treatment, the International Intraocular
34 Retinoblastoma Classification (IIRC) (Murphree 2005) system was developed. This
35 system is largely based on natural progression of disease from small tumors away from
36 the macula (easily treatable with laser therapy) and larger, central tumors with variable
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 degrees of seeding and retinal detachment (requiring chemotherapy in addition to focal
4 therapy). Modifications to the original IIRC were later introduced by another group
5 (Shields et al. 2006), making it difficult to compare across studies and centers
6
7 (Novetsky et al. 2009). The critical differences between the classification systems have
8 previously been reviewed (Dimaras et al. 2015). Other classification schemes include
9
10 staging of extraocular retinoblastoma (Chantada et al. 2006) and staging of vitreous
11
12 seeding (Francis et al. 2015; Francis et al. 2016; Munier 2014).
13
14
15
16
17
18
19

20 As with other cancers, retinoblastoma is also staged using the American Joint
21 Commission on Cancer (AJCC)'s "Tumor Node Metastasis" (TNM) classification
22 system. The most recent 8th edition of the TNM (Mallipatna et al. 2017) aims to provide
23 a way forward for retinoblastoma classification given the above eye-based classification
24 confusion. The Tumor stage is first applied per eye based on clinical features, and the
25 patient's score is based on the most advanced eye (Mallipatna et al. 2017). Radiology
26 plays an important role in determining the Metastasis stage, particularly in delineating
27 any involvement of the CNS. The 8th edition of the TNM also includes a new feature,
28 the additional "H" or heritable trait, which denotes risk of multifocal tumors that can
29 affect both eyes and brain (trilateral retinoblastoma). As yet, trilateral retinoblastoma is
30 not staged by the TNM system. In fact, no other tumors of the CNS are staged by TNM,
31 as tumor size is not a prognostic indicator, the brain and spinal cord do not have a
32 lymphatic system, and metastases are rarely distant (Laws Jr. et al. 2017).
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50 Retinoblastoma is a unique CNS tumor in this respect, as tumor size is prognostic, it
51 can affect preauricular, submandibular or cervical nodes, and distant metastases occur
52
53
54
55 (Mallipatna et al. 2017).
56
57
58
59
60

1
2
3 **Pathology.** Retinoblastoma is a small round blue-cell tumor (Fig. 1d-e), and thus
4 bears histologic similarity to other childhood nervous system tumors including
5 neuroblastoma and medulloblastoma. Cells are primarily composed of large basophilic
6 nuclei and little cytoplasm. The tumor is highly proliferative, displaying abundant
7 mitoses and necrosis. Cells may take on a polygonal shape and mimic cobblestones
8 when packed together (Tso 1980). Often, collars of viable cells can be observed around
9 a blood vessel, surrounded by necrosing cells (Fig. 1f). Tumors display varying degrees
10 of differentiation. Cellular differentiation is primarily in the form of Flexner-Wintersteiner
11 rosettes and Homer Wright rosettes (Tso 1980) (Fig. 1e). Flexner-Wintersteiner rosettes
12 are composed of an 'empty' lumen surrounded by columnar cells (Wippold and Perry
13 2006). Homer Wright rosettes consist of cells surrounding a central lumen made up of
14 their processes (Wippold and Perry 2006). While each type is individually common in
15 other neural tumors, the dual presence of Homer Wright and Flexner-Wintersteiner
16 rosettes is pathognomonic for retinoblastoma.
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35

36 Retinoma histopathology is distinct from retinoblastoma (Fig. 1g). This benign
37 precursor is composed of sparsely spaced round cells, and does not contain rosettes.
38 Instead, it is characterized by the presence of fleurettes, composed of clusters of cells
39 with long, bulbous cytoplasmic processes, mimicking the *fleur-de-lys* (Dimaras et al.
40 2009; Dimaras et al. 2008). Retinoma is observed next to retinoblastoma in 16-20% of
41 eyes enucleated for retinoblastoma (Dimaras et al. 2008; Eagle 2009).
42
43
44
45
46
47
48
49
50

51 Cellular differentiation has not been conclusively linked to prognosis, and thus does
52 not form part of the histological evaluation of tumors. However, the degree of anaplasia
53 evident in retinoblastoma has been shown to correlate with prognosis (Mendoza et al.
54
55
56
57
58
59
60

1
2
3 2015), but this has not yet become part of routine histological evaluation. The pathology
4
5 TNM (pTNM) classification determines extent of tumor involvement of the optic nerve,
6
7 choroid, sclera and anterior segment (Finger 2009; Gallie et al. 2016; Mallipatna et al.
8
9 2017). High risk of metastasis (pT3) is conveyed by >3 mm of tumor in the choroid (the
10
11 vascular layer of the eye, under the retina), tumor extending beyond the lamina cribrosa
12
13 of the optic nerve (the perforated or 'mesh-like' structure in the sclera through which the
14
15 fibers of the optic nerve exit the eye), or significant invasion of the sclera. Extraocular
16
17 disease (pT4) is marked by tumor at the cut end of the nerve, involvement of the
18
19 episclera, or invasion of adjacent bone, eyelid, conjunctiva, or muscle (Mallipatna et al.
20
21 2017).
22
23
24
25

26
27 **Genetics.** Retinoblastoma is perhaps best known to cancer biologists as the
28
29 inspiration for the "two-hit hypothesis" for oncogenesis, which states that loss of both
30
31 alleles of a tumor suppressor gene are necessary to initiate cancer. Working in the pre-
32
33 genomic era, Alfred Knudson noted an earlier age of onset for bilateral retinoblastoma
34
35 than for unilateral (Knudson 1971). His mathematical analysis implied two rate-limiting
36
37 steps were needed for unilateral retinoblastoma to develop, while only a single rate-
38
39 limiting step was required for bilateral cases. Fifteen years later, the "retinoblastoma
40
41 gene," *RB1*, was cloned, confirming Knudson's prediction (Friend et al. 1986; Fung et
42
43 al. 1987; Lee et al. 1987). Unilateral patients (usually) have lost both wild-type alleles of
44
45 *RB1* in a susceptible retinal cell (two hits), leading to a single, unifocal tumor (Fig. 2).
46
47 Conversely, all bilateral patients have a germline mutation in *RB1*, thus only require a
48
49 second hit to initiate cancer, which (usually) happens in multiple cells, in both eyes. The
50
51 situation is complicated somewhat by low-penetrance alleles, which can be mutated in
52
53
54
55
56
57
58
59
60

1
2
3 the germline without promoting bilateral disease (Lohmann et al. 1994). Because of this,
4
5 approximately 15% of unilateral cases have a heritable mutation.
6
7

8
9 The irony is not lost on us that while being a visible tumor, retinoblastoma can rob
10
11 vision from the children it affects. If patients grow up to have children of their own, they
12
13 should learn if they have a heritable mutation that could affect their offspring. For all
14
15 families with heritable retinoblastoma, the “visible feature” of retinoblastoma that allows
16
17 early detection is knowledge of the *RB1* mutation. Prenatal genetic detection coupled
18
19 with early term delivery (37-38 weeks’ gestation) of the affected infant allows clinical
20
21 teams to monitor the newborn’s retina for the earliest sign of tumor and treat it
22
23 immediately (Soliman et al. 2016).
24
25
26
27

28 The *RB1* gene encodes pRB, a key negative regulatory transcription factor
29
30 governing the G₁ to S phase cell cycle transition by blocking the interactions of DNA-
31
32 binding E2F and DP transcription factors with DNA (Dick and Rubin 2013). In response
33
34 to mitogen-stimulated cyclin-dependent kinase signaling, normal pRB is
35
36 hyperphosphorylated, releasing it from E2F interactions, allowing these factors to
37
38 activate transcription. pRB also has a growing spectrum of roles in differentiation,
39
40 chromatin remodeling, genome stability, and apoptosis (Dimaras and Corson 2016;
41
42 Velez-Cruz and Johnson 2017).
43
44
45
46

47 Over 1000 mutations in *RB1* have been documented in retinoblastoma tumors,
48
49 including missense and nonsense mutations, splicing mutations, frameshifts, micro- and
50
51 macrodeletions, and promoter methylation (Lohmann and Gallie 2004). Despite this, a
52
53 small fraction of unilateral cases lack identified *RB1* mutations, so it was long postulated
54
55
56
57
58
59
60

1
2
3 that an alternative mechanism of retinoblastomagenesis might be possible. As part of
4 an international team, in 2013 we identified that 1.4% of unilateral retinoblastoma,
5
6 lacking *RB1* mutations, instead showed amplification of *MYCN* (Rushlow et al. 2013)
7
8 (Fig. 2), a transcription factor-encoding gene more frequently associated with the
9
10 pediatric peripheral nervous system tumor, neuroblastoma (Ruiz-Perez et al. 2017).
11
12 This finding raises interesting questions about the parallels between retinoblastoma and
13
14 other neuronal tumors; see below.
15
16
17
18
19

20
21 Even in retinoblastoma tumors with a defined *RB1* mutation, further mutational
22
23 events are needed for malignancy (Corson and Gallie 2007). Retinal cells homozygous
24
25 for *RB1* loss can form the benign tumor, retinoma, but develop other genomic changes
26
27 in the progression to malignancy (Dimaras et al. 2008). The spectrum of changes is
28
29 characterized by relatively few mutated genes, especially compared to common adult
30
31 epithelial cancers. The transcriptional corepressor *BCOR* (BCL6 corepressor) is the
32
33 most commonly mutated gene in retinoblastoma after *RB1* (Zhang et al. 2012).
34
35 However, retinoblastoma displays a distinct pattern of genomic gains and losses,
36
37 notably 1q, 2p, and 6p gain, and 16q loss (Kooi et al. 2016b). Candidate progression
38
39 genes with functional evidence in these regions include *MDM4* and *KIF14* on 1q,
40
41 encoding the p53 regulator mouse double minute 4 and the oncogenic motor protein
42
43 kinesin family member 14, respectively. *MYCN* is the most commonly amplified gene on
44
45 2p, while on 6p, the best-studied genes are the DNA-binding proto-oncogene *DEK* and
46
47 the transcription factor *E2F3*. Genes commonly lost on 16q include *CDH11*, encoding
48
49 the adhesion protein cadherin-11, and *RBL2*, encoding the retinoblastoma family
50
51 member p130 (Kooi et al. 2016b; Theriault et al. 2014). In addition, aberrant methylation
52
53
54
55
56
57
58
59
60

1
2
3 is seen in the retinoblastoma genome (Benavente and Dyer 2015), including of the
4
5 oncogenic kinase *SYK* (spleen tyrosine kinase). As in other cancers, a variety of
6
7 microRNAs are also dysregulated in retinoblastoma (Singh et al. 2016), including the
8
9 miR-17~92 cluster and miR-106b~25 (Conkrite et al. 2011).
10
11

12
13 **Treatment and prognosis.** Treatment of retinoblastoma is complex and varied.
14
15 Eyes containing tumors that display clinical features threatening to extend beyond the
16
17 globe may be surgically removed (enucleation) and histologically assessed to determine
18
19 risk of metastasis. Eye salvage may be attempted on less severely affected eyes
20
21 (Dimaras et al. 2015; National Retinoblastoma Strategy 2009), with focal therapy (laser,
22
23 cryotherapy) (Hamel et al. 2000), brachytherapy (Hernandez et al. 1993), and/or
24
25 chemotherapy. Chemotherapy may be systemic, usually with a cocktail of vincristine,
26
27 etoposide, and carboplatin (Chan et al. 1996; Gallie et al. 1996), intra-arterial (Yousef et
28
29 al. 2016), and/or intravitreal (Munier et al. 2012a; Munier et al. 2012b)). Melphalan is the
30
31 preferred drug for these latter modalities. External beam radiation is another effective
32
33 treatment, however this is not preferred due to its added second cancer risks (Temming
34
35 et al. 2016). Trilateral retinoblastoma treatment and outcomes are discussed in a later
36
37 section.
38
39
40
41
42
43

44
45 Left untreated, retinoblastoma will grow and extend beyond the eye. Commonly, it
46
47 invades the regional lymph nodes, bone, bone marrow, and the central nervous system.
48
49 Extension into the CNS can be detected with radiologic imaging. Prognosis for CNS
50
51 disease is much worse than for bone-marrow, as treatment with systemic chemotherapy
52
53 is impeded by the blood-brain barrier (Mallipatna et al. 2017). Cytologic examination can
54
55 detect tumor dissemination in CSF and bone marrow. Monitoring of CSF disease can be
56
57
58
59
60

1
2
3 also done molecularly, by looking for tumor-specific (non-germline) *RB1* mutations or
4
5 post-*RB1* loss genomic gains and losses (Bowles et al. 2007; Dimaras et al. 2010b;
6
7 Racher et al. 2016), or tumor-derived *GD2* or *CRX* mRNA expression (Laurent et al.
8
9 2010; Laurent et al. 2013; Torbidoni et al. 2015).

10
11
12
13 Individuals with a constitutional *RB1* mutation have an increased risk of developing
14
15 second primary tumors, like osteosarcoma, melanoma, lung or bladder cancer later in
16
17 life (MacCarthy et al. 2013). Surveillance for second primary malignancies is not yet
18
19 supported by strong evidence or broad consensus, though some suggest there may be
20
21 a role for annual screening by whole body MRI (Friedman et al. 2014; Kamihara et al.
22
23 2017). More commonly, retinoblastoma survivors are educated on second primary
24
25 tumor risks and instructed to be vigilant about potential signs of new malignancies
26
27 (Kamihara et al. 2017).
28
29
30
31

32
33 Guidelines for treatment in high income (National Retinoblastoma Strategy 2009)
34
35 and low-and-middle income countries (Kenyan National Retinoblastoma Strategy Group
36
37 2014) are similar, although they account for differences in availability of resources and
38
39 stage of disease at presentation (*i.e.*, low-and-middle-income countries see more cases
40
41 of extraocular and metastatic disease). Patient outcomes are notably worse in low-and-
42
43 middle income countries than in high (Dimaras et al. 2015), and further research is
44
45 needed to address social determinants affecting access to quality care (Dimaras et al.
46
47 2010a).
48
49
50
51

52 **IMAGING RETINOBLASTOMA**

53
54
55
56
57
58
59
60

1
2
3 **Clinical vignette.** An adult survivor of bilateral retinoblastoma is pregnant with her
4
5 first child. She undergoes prenatal genetic testing. Her fetus is found to carry her
6
7 familial *RB1* mutation and is therefore at risk of developing retinoblastoma. Shortly after
8
9 birth, the infant's eyes are visually examined, and the retina appears normal in each
10
11 eye. Monthly examinations are scheduled, during which the ophthalmologist inspects
12
13 each eye with the indirect ophthalmoscope, and an imaging specialist documents the
14
15 fundus with digital images. At the second examination after birth, the ophthalmologist
16
17 still does not see any tumors in the eyes. A clear fundus is documented in each eye
18
19 using a high-resolution fundus camera. Next, the imaging specialist uses Optical
20
21 Coherence Tomography (OCT) to image the eyes. Surprisingly, the OCT reveals a tiny
22
23 lump within the inner nuclear layer of the retina in the left eye. Looking back at the
24
25 fundus images, the ophthalmologist notes a slight haze in the exact spot picked up by
26
27 OCT: it is a tiny tumor, originally missed on examination of the photographic images.
28
29 The tumor is treated with focal therapy, preventing its growth and sparing vision (Based
30
31 on similar cases previously reported; Rootman et al. 2013; Soliman et al. 2016).
32
33
34
35
36
37

38 **Fundus imaging.** Images of the fundus (interior surface of the eye), which become
39
40 part of the medical record, facilitate consultation and collaboration, and precise tracking
41
42 of tumor response or resistance to treatment. This kind of longitudinal, visual
43
44 documentation is unique amongst CNS tumors. Before photographic imaging equipment
45
46 was a standard part of ophthalmic care, retinal drawings (Wilson 1975) were used to
47
48 map retinal topography, lesions, relevant landmarks and treatments applied, as
49
50 observed through the indirect ophthalmoscope (Dvorak and Russell 2011). Retinal
51
52 imaging has changed practice by providing a way to digitally document the eye, but
53
54
55
56
57
58
59
60

1
2
3 retinal drawings still remain an important part of learning to understand the disease
4
5 trajectory.
6
7

8
9 Digital retinal imaging via portable fundus camera has revolutionized clinical
10 documentation of retinoblastoma (Fig. 1b, 3a, 3d), allowing comparison of pre- and
11 post-treatment images (Romanowska Dixon and Morawski 2017) and facilitating
12 consultation between centers (National Retinoblastoma Strategy 2009). The RetCam™
13 (Clarity Medical) captures high-resolution, wide-angle photographs, and with scleral
14 depression, allows imaging of the retina up to the *ora serrata* (the anterior edge of the
15 retina) (National Retinoblastoma Strategy 2009). Similarly, the ICON camera (Phoenix
16 Technology Group), produces wide-field, high-contrast, high-resolution fundus images.
17
18
19
20
21
22
23
24
25
26
27

28 Unlike fundus drawings, which depict the entire retina in one image, fundus images
29 are partial views of the entire retina and must be stitched together to get a whole-retina
30 view. Fluorescein angiography with portable fundus camera imaging is also important to
31 document vascularization, especially for follow-up of advanced tumors (Kim et al. 2014).
32
33
34
35
36
37

38 **Ultrasound.** The B-scan (10 MHz) 2D ultrasound is commonly used for ocular
39 imaging, and has been a part of the diagnostic toolkit in ophthalmology for decades
40 (Giglio and Sherman 1979; Kendall et al. 2015; Mrochuk 1990). It is able to distinguish
41 between ocular structures such as lens, choroid, retina and sclera, and image and
42 measure aberrations in the eye, such as tumors or retinal detachment. Importantly for
43 retinoblastoma, B-scan ultrasound allows visualization of calcification, a key feature of
44 these tumors, and thus can help confirm diagnosis (National Retinoblastoma Strategy
45 2009; Novotny and Krasny 1990) (Fig. 3b).
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 High frequency B-scan ultrasonography (20-50MHz), also known as ultrasound
4 biomicroscopy (UBM), produces images with higher resolution than traditional B-scan
5 (Pavlin et al. 1990). It first showed promise in the imaging of anterior segment tumors
6 more consistently than B-scan (Pavlin et al. 1992; Reminick et al. 1998). For
7 retinoblastoma, UBM has been shown to be essential for determining the proximity of
8 the tumor to the anterior portion of eye (Vasquez et al. 2011). These are important
9 diagnostic details that assist with accurate classification at presentation.
10
11
12
13
14
15
16
17
18
19

20 Furthermore, like other imaging modalities, ocular ultrasonography also allows
21 monitoring of tumor regression as treatment progresses, primarily by comparing the size
22 of the tumor at each examination to measurements taken at baseline. Unlike the use of
23 intraoperative ultrasound for detection of residual disease in brain tumors (Bohringer et
24 al. 2009), ocular ultrasound cannot currently distinguish between active and inactive
25 retinoblastoma tumor.
26
27
28
29
30
31
32
33
34

35 **Magnetic Resonance Imaging (MRI).** As with other CNS tumors, MRI can provide
36 important diagnostic and prognostic information in retinoblastoma (Fig. 3c) and is vital
37 for screening for trilateral retinoblastoma (see below). MRI can also aid in characterizing
38 the tumor in cases where it is not visible, for instance if it is behind a cataract-containing
39 lens.
40
41
42
43
44
45
46

47 Where available, MRI is often used as part of the workup of all patients with
48 retinoblastoma, as it can provide vital information about high-risk pathological features
49 prior to enucleation (de Graaf et al. 2012). These include: optic nerve invasion
50 evidenced by thickening; massive choroidal invasion evidenced by thickening or
51
52
53
54
55
56
57
58
59
60

1
2
3 irregularities, scleral invasion evidenced by signal-enhancing tissue beyond the choroid,
4 and intracranial invasion into the suprasellar region (Razek and Elkhamary 2011).
5
6 However, sensitivity for detecting these high-risk features varies considerably (de Jong
7
8 et al. 2014a). High field-strength MRI can also confirm retinoblastoma diagnosis by
9
10 corroborating the calcifications observed by ultrasound or fundus imaging (Galluzzi et
11
12 al. 2009), and can detect vitreous seeds or anterior segment involvement (Razek and
13
14 Elkhamary 2011). Again, these uses are particularly valuable when fundus imaging is
15
16 not possible. Note that computerized tomography (CT) imaging is generally avoided in
17
18 retinoblastoma due to the radiation risks, especially in patients with a germline *RB1*
19
20 mutation, already at increased risk for second primary tumors.
21
22
23
24
25
26

27 In intracranial tumors like gliomas, intraoperative MRI has assumed a pivotal role, to
28
29 detect removal of diseased tissue during surgery (Hlavac et al. 2017). Intraoperative
30
31 MRI is not necessary in retinoblastoma, as enucleation usually removes the entirety of
32
33 the tumor, unless extraocular spread has been previously detected, or high risk features
34
35 are subsequently discovered on pathology. However, one retinoblastoma case report
36
37 describes the use of intraoperative MRI to track the delivery and tumor penetration of
38
39 intra-arterial melphalan delivered in a cocktail with gadolinium (Materin et al. 2012).
40
41
42
43

44 **Optical coherence tomography (OCT).** OCT, a non-invasive imaging technique
45
46 based on differential near-infrared light reflection, offers a powerful tool for imaging
47
48 retinoblastoma, with resolution exceeding that of ultrasound or MRI. Conceptually
49
50 similar to ultrasound, spectral domain (SD) OCT can generate high resolution, cross-
51
52 sectional images of tissues where light can penetrate (Fujimoto and Swanson 2016), so
53
54 has found utility in dermatology, urology, and in particular, ophthalmology, where it is
55
56
57
58
59
60

1
2
3 routinely used in adult clinics. It has also been used in the CNS: for *ex vivo* analysis of
4 gliomas (Valdes et al. 2016) and medulloblastoma (Vuong et al. 2015), and is being
5
6 trialed for intraoperative imaging of gliomas to detect residual tumor, as is also done via
7
8 ultrasound and MRI (Bohringer et al. 2009).
9
10

11
12
13 Recently, with the advent of hand-held intraoperative OCT systems, OCT has
14 become popular for pediatric ophthalmology as well, including retinoblastoma
15
16 assessment (Do et al. 2017). Initial publications were case reports indicating the value
17
18 of OCT for detecting cavitory retinoblastoma (Mashayekhi et al. 2005) and reasons for
19
20 visual loss (such as retinal detachment) post-therapy (Shields et al. 2005).
21
22 Subsequently, OCT showed utility for documenting response to therapy, spotting edge
23
24 recurrence, and notably, detecting “invisible” tiny retinoblastoma (Fig. 3d-f) (Rootman et
25
26 al. 2013), as well as assessing foveal anatomy, which impacts the likelihood of visual
27
28 function post-therapy (Cao et al. 2014; Samara et al. 2015). One case report even
29
30 documented optic nerve head disease, usually detected by MRI (see above) (Yousef et
31
32 al. 2012). OCT’s ability to look “behind” small features such as vitreous seeds to the
33
34 underlying tumor or normal retina can be valuable for assessing retinoblastoma
35
36 comprehensively.
37
38
39
40
41
42
43

44 This growing body of work also contributed to an ongoing debate on the cell of origin
45
46 of retinoblastoma, as some tiny tumors detected by OCT seem to originate in the inner
47
48 nuclear layer (Rootman et al. 2013) (Fig. 3f), while others are more localized to the
49
50 outer nuclear layer, suggestive of a cone precursor origin for at least some
51
52 retinoblastoma (Berry et al. 2016), which is consistent with experimental data (Xu et al.
53
54 2014).
55
56
57
58
59
60

1
2
3 Although not yet in use for retinoblastoma, recently-developed OCT angiography
4 holds considerable promise for documenting vascularization and blood flow in and
5 around tumors (Gao et al. 2016). However, OCT does have limitations: it images the
6 periphery of the retina poorly (although technology for widefield OCT is improving), and
7 relies on transparent media: large tumors and/or cataracts limit its usefulness. Despite
8 this, OCT for retinoblastoma is usually successful and can guide treatment decisions
9 (Soliman et al. 2017b). With time, OCT will doubtless assume a greater role in the
10 staging and management of retinoblastoma, taking true advantage of the accessibility of
11 the eye to manage this cancer.
12
13
14
15
16
17
18
19
20
21
22
23
24

25 **Imaging animal models.** The wealth of imaging tools available for the eye has
26 made longitudinal studies of retinoblastoma animal models possible, complementing
27 more traditional histological analyses (Fig. 3g). The advent of small animal intraocular
28 imagers enabled documentation of intraocular tumors in both transgenic and orthotopic
29 xenograft models of the cancer. In particular, coupling fluorescence and brightfield
30 imaging of GFP-expressing xenografts allowed qualitative assessment of tumor growth
31 and (importantly) dissemination within the eye (Corson et al. 2014). Similarly, a number
32 of preclinical therapeutic studies have included qualitative fundus and fluorescein
33 angiography images (Brennan et al. 2011; McEvoy et al. 2011; Zhang et al. 2012). In
34 the future, quantification of fluorescence should allow volumetric analysis of tumor
35 growth, as is currently done using bioluminescence of luciferase-expressing xenografts
36 (Corson et al. 2014; Ji et al. 2009; Laurie et al. 2005).
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52

53 MRI has also been employed in preclinical treatment trials, and in one report was
54 used for volumetric estimation of tumor (McEvoy et al. 2011). Ultrasound has also been
55
56
57
58
59
60

1
2
3 used for animal models in limited cases (Brennan et al. 2011); one study showed
4 fundus, ultrasound and MRI images of transgenic animals in a treatment trial, but did
5 not use these images for assessing efficacy (Nemeth et al. 2011).
6
7
8
9

10
11 OCT has become a favored method for detecting lesions, especially in genetic
12 models. The first work in this area was done with custom-built OCT apparatus, enabling
13 detection of intraretinal tumors in the SV40 T-antigen driven mouse model of
14 retinoblastoma (TAg-RB) (Ruggeri et al. 2007), and assessing their response to therapy
15 (Cebulla et al. 2008). Even retinal tumors *in utero* could be detected through the uterine
16 horn (Larina et al. 2012). TAg-RB tumors have also been documented by ultrasound
17 (Foster and Brown 2012).
18
19
20
21
22
23
24
25
26
27

28 More recently, using a commercially-available small animal OCT system, we showed
29 that this technique can detect the earliest signs of tumors in the TAg-RB model,
30 corresponding to their first appearance by histology (Fig. 3g) (Wenzel et al. 2015), and
31 we used this finding to show that overexpression of the oncogene *Kif14* accelerates not
32 just tumor growth, but tumor initiation in this model as well (O'Hare et al. 2016).
33
34
35
36
37
38
39

40
41 OCT has proven useful for xenografts: intravitreal xenografts could be monitored
42 (Corson et al. 2014; Tschulakow et al. 2016) and subretinal xenografts could be rapidly
43 assessed by a combination of OCT and funduscopy (Lemaitre et al. 2017). Of course,
44 OCT assessment of morphology of xenografts is less clinically relevant than the
45 morphology of tumors arising intraretinally as in genetic retinoblastoma models.
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 methods to volumetrically assess lesions on OCT (Ruggeri et al. 2009; Sulaiman et al.
4
5 2015).

6 7 8 **MYCN-AMPLIFIED RETINOBLASTOMA**

9
10 **Clinical vignette.** A 1-month-old infant with no family history of retinoblastoma has a
11 large retinoblastoma identified in one eye. On enucleation, no rosettes are noted, but
12 the high-risk pathological feature of optic nerve invasion is present. Since early-onset,
13 aggressive tumors are often indicative of a germline *RB1* mutation, heritable disease is
14 suspected, with the concomitant risk of tumors in the fellow eye and a need for lifelong
15 surveillance and risk to offspring. But genetic analysis of the enucleated tumor fails to
16 find any mutated *RB1* alleles, despite >96% detection rate in specialized labs (Soliman
17 et al. 2017a). However, further analysis of common copy number changes in
18 retinoblastoma reveals that the oncogene *MYCN* is amplified to 53 copies in this tumor,
19 and on subsequent re-review, the pathologist notices some neuroblastoma-like
20 histological features. These findings strongly suggest *MYCN*-driven disease, which is
21 not heritable, leaving this child at only population risk for future malignancies.
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38

39 **Discovery and characteristics.** *MYCN* retinoblastoma was identified based on
40 careful analysis of over 1000 tumor genotypes (Rushlow et al. 2013). Although *MYCN*
41 amplification had been documented in occasional retinoblastoma since the *MYCN* gene
42 was first identified (Gilbert et al. 1981), this large-scale study was needed to reveal that
43 *MYCN* amplification is much more common amongst unilateral retinoblastoma without a
44 detectable *RB1* mutation. This finding has since been replicated in other cohorts
45 (Ewens et al. 2017; Kooi et al. 2016a; McEvoy et al. 2014), but it is important to note
46 that *MYCN* retinoblastoma is currently only identifiable after enucleation. Retrospective
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 analysis of *MYCN* retinoblastoma revealed several further differentiating features (Fig.
4 4). Clinically, these tumors are amongst the very earliest-onset unilateral tumors, and
5 often had high-risk pathological features, although there is not yet sufficient evidence to
6 conclude that *MYCN* amplification has a dramatic effect on aggressiveness, as it does
7 in neuroblastoma or medulloblastoma (Ruiz-Perez et al. 2017). Histopathologically,
8 these tumors also differ from *RB1*^{-/-} retinoblastoma. Comparatively, they show more
9 rounded, undifferentiated cells, with prominent nucleoli (Fig. 4c), and lack the nuclear
10 molding, differentiated rosettes, and extensive calcification commonly seen in
11 retinoblastoma. Again, the histology of *MYCN* retinoblastoma is more similar to
12 neuroblastoma than it is to *RB1*^{-/-} retinoblastoma.
13
14
15
16
17
18
19
20
21
22
23
24
25
26

27 **Molecular features.** Beyond the lack of *RB1* mutations, *MYCN* retinoblastoma had
28 fewer copy number alterations than *RB1*^{-/-} tumors in one study (Rushlow et al. 2013),
29 although this was not seen in a subsequent report (Ewens et al. 2017). *MYCN*
30 retinoblastoma were also less likely to display the characteristic chromosomal gains and
31 losses of retinoblastoma (1q and 6p gain, 16q loss), instead showing some variations in
32 common with neuroblastoma (17q gain, 11q loss) (Rushlow et al. 2013).
33
34
35
36
37
38
39
40
41

42 *MYCN* retinoblastomas have functional, hyperphosphorylated pRB (Ewens et al.
43 2017), and high levels of N-Myc protein (Rushlow et al. 2013). The fact that pRB is
44 expressed, yet inactivated by post-translational modification, strongly implies that
45 genetic changes at the *RB1* locus are not driving this disease. The SKP2-p27 axis
46 leading to pRB phosphorylation was not activated in 3 of 4 *MYCN* retinoblastoma
47 (Ewens et al. 2017), suggesting that this *MYCN*-activated pathway is not a key driver in
48 *MYCN* retinoblastoma, unlike in neuroblastoma (Evans et al. 2015).
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Interestingly, high retinal *Mycn* levels alone (driven by the Pax6 α enhancer) could
4 not initiate retinoblastoma-like tumors in mice, but could cooperate with *Rb1* loss to form
5 tumors (which normally require loss of another retinoblastoma family member such as
6 *p107*) (Wu et al. 2017). This discovery also offered a caution toward *MYCN*-targeted
7 therapy: when *Mycn* levels were reduced in this mouse model, tumors reoccurred with
8 *Mycn*-independence (Wu et al. 2017). Further insight into how *MYCN* amplification
9 leads to pRB inactivation by hyperphosphorylation and drives the human tumors is
10 needed. Perhaps the Pax6 α enhancer does not drive expression in the retinal cell type
11 susceptible to *Mycn*-driven retinoblastoma; *Mycn* overexpression alone can promote
12 cancer in other tissues, as observed with the tyrosine hydroxylase-driven *Mycn*
13 neuroblastoma model (Weiss et al. 1997). In the absence of perfect mouse models, cell
14 lines and patient-derived xenografts will be best suited for these experiments, but given
15 the rarity of *MYCN* retinoblastoma, few are currently available.
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33

34 **Are *MYCN*-amplified ocular tumors retinoblastoma?** Despite the
35 histopathological and genetic similarities with neuroblastoma, there is no reason to
36 believe that “*MYCN* retinoblastoma” is not retinoblastoma: it apparently arises in a
37 retinal neuronal precursor, and (based on a small number of tumors) has a gene
38 expression profile not statistically distinct from that of a major group of retinoblastoma,
39 characterized by low “photoreceptoriness”, but high expression of RNA biogenesis and
40 M phase genes (Kooi et al. 2015). Thus, to date it is unclear if *MYCN* retinoblastoma
41 derives from a different retinal cell of origin than *RB1*^{-/-} retinoblastoma, or if the cell of
42 origin is the same, but the initiating *MYCN* amplification event pushes these cells into a
43 distinct phenotype.
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

TRILATERAL RETINOBLASTOMA

Clinical vignette. A 6-month old presents with a 2-week history of leukocoria in one eye. Upon ophthalmic examination, the child is diagnosed with unilateral retinoblastoma. As part of routine work-up, the child undergoes CT of head and both orbits. The CT reveals an intracranial midline tumor. Cytologic examination of the CSF shows presence of malignant cells. The child undergoes treatment for trilateral retinoblastoma, which includes high-dose chemotherapy followed by autologous stem cell transplant. The child is alive and well 10 years post-treatment. (Based on a previously reported case; Dimaras et al. 2015; Dimaras et al. 2011).

A 4-month old presents to the emergency room with atypical eye movements and overgrowth syndrome. A CT scan reveals a suprasellar tumor (Fig. 5). The eyes are not examined at this time. The tumor is biopsied and shows a small blue cell tumor with abundant Flexner-Wintersteiner rosettes. The eyes are then examined, and reveal multifocal tumors in both eyes. Systemic and intrathecal chemotherapy for trilateral retinoblastoma is prescribed. During the placement of the intrathecal catheter, the treating physicians observe tumor seeding along the needle tract of the initial biopsy. The child's tumor reoccurs and she dies. (Based on a previously reported case; (Dai et al. 2008; Dimaras et al. 2011).

Origins and Pathology. Trilateral retinoblastoma, first described in 1977 (Jakobiec et al. 1977) and coined in 1980 (Bader et al. 1980), is the heritable form of retinoblastoma associated with an intracranial tumor. The intracranial tumors most commonly affect the pineal gland, as well as the suprasellar or intrasellar region of the brain (Fig. 5). Pineal tumors are generally smaller than non-pineal tumors in trilateral

1
2
3 retinoblastoma (de Jong et al. 2014b). Benign pineal cysts have also been observed
4
5 with retinoblastoma (Beck Popovic et al. 2006; Gupta et al. 2016; Karatza et al. 2006).
6
7 In rare cases pineal cysts can transform into malignant tumors, suggesting they should
8
9 be monitored over time (de Jong et al. 2016). Cystic normal pineal glands, however, are
10
11 also regularly observed in children; their size is often comparable to solid and cystic
12
13 pineoblastoma (Sirin et al. 2016). This makes it challenging to know which cystic lesions
14
15 require follow-up, and which do not. A classification for pineal glands has been
16
17 proposed to differentiate glands based on absence or presence of cysts, number of
18
19 cysts, and enlargement (Type 0-4) (Sirin et al. 2016). The European Retinoblastoma
20
21 Imaging Collaboration proposed guidelines for follow-up of cystic pineal lesions based
22
23 on this classification: they recommend monitoring Type 3 and 4 lesions (multicystic with
24
25 enlargement) by routine MRI for changes in size or morphology of the solid component
26
27 of the lesion (Sirin et al. 2016). It is sometimes equally challenging to differentiate large
28
29 solid pineal glands from pineoblastoma (Galluzzi et al. 2016).
30
31
32
33
34
35

36 Trilateral retinoblastoma often presents with leptomeningeal metastasis or CSF
37
38 involvement, which is difficult to cure. The histological features of the intracranial tumor
39
40 are identical to those of retinoblastoma (Fig. 5c). Because of its rarity, little work on the
41
42 molecular genetics of this tumor has been reported (Li et al. 2005). Mouse models may
43
44 yet offer some insights: 15%-27% of TAg-RB mice develop primitive neuroectodermal
45
46 tumors, analogous to the parasellar and suprasellar tumors arising in patients with
47
48 trilateral retinoblastoma (Marcus et al. 1991; O'Brien et al. 1990). The trilateral tumors in
49
50 mice have histological features consistent with their human counterparts (Marcus et al.
51
52 1991). However, this murine retinoblastoma model does not develop pineoblastoma
53
54
55
56
57
58
59
60

1
2
3 (Marcus et al. 1991), although other T-antigen-driven tumor models do (Marcus et al.
4
5 1996). Also, *Rb1*^{+/-} mice with loss of p53 develop pineoblastomas, but these mice do not
6
7 develop retinal tumors (Williams et al. 1994). Despite the existence of these models, no
8
9 preclinical studies on trilateral retinoblastoma have yet been reported.
10
11

12
13 In addition to predisposition by *RB1* mutation, pineoblastoma alone is associated
14
15 with germline mutations in *DICER1* (de Kock et al. 2014). In murine retinoblastoma
16
17 models, *Dicer1* is a haploinsufficient tumor suppressor (Lambertz et al. 2010). Further
18
19 investigation is warranted into the development of pineoblastoma within and without the
20
21 context of retinoblastoma.
22
23

24
25 **Epidemiology.** The incidence of trilateral retinoblastoma among patients with
26
27 heritable retinoblastoma is 3.5% (de Jong et al. 2015). Prior systemic chemotherapy to
28
29 treat retinoblastoma is associated with decreased risk of developing an intracranial
30
31 tumor (Shields et al. 2001). Suprasellar or intrasellar tumors are diagnosed earlier than
32
33 pineal, and often concurrently with the retinoblastoma (Kivela 1999). In contrast, 60% of
34
35 pineal tumors are diagnosed within 1 year of initial retinoblastoma diagnosis, suggesting
36
37 that routine screening by MRI could contribute to earlier diagnosis (de Jong et al.
38
39 2014b). Some centers screen by MRI every 6 months until 5 years of age (Kamihara et
40
41 al. 2017), however it is unclear if this approach is warranted or effective (De Ioris et al.
42
43 2014).
44
45
46
47
48
49

50 **Becoming treatable.** Treatment for trilateral retinoblastoma generally involves
51
52 chemotherapy delivered systemically and intrathecally via an Ommaya reservoir,
53
54 followed by high-dose chemotherapy and autologous stem cell rescue (Dimaras et al.
55
56
57
58
59
60

1
2
3 2011). Surgical treatment has been attempted in some cases; however, complete
4 resection is difficult due to the locations of the intracranial tumors (Dunkel et al. 2010).
5
6 Craniospinal radiation, while effective, is not preferred because of its long-term
7
8 developmental, neurocognitive and endocrine damage (Duffner et al. 1985; Mulhern et
9
10 al. 1999). Indeed, the use of radiation in the treatment of trilateral retinoblastoma has
11
12 declined in recent years (de Jong et al. 2014b).
13
14
15
16
17

18 Survival from trilateral retinoblastoma has improved over time, most notably with the
19
20 introduction of high-dose chemotherapy and autologous stem cell transplant (de Jong et
21
22 al. 2014b). Looking at outcomes before and after 1995, when chemotherapy changed
23
24 treatment for retinoblastoma, the 5-year survival for pineal trilateral retinoblastoma has
25
26 increased from 6% to 44%, and non-pineal from 0 to 57% (de Jong et al. 2014b; Kivela
27
28 1999). The presence of leptomeningeal metastases considerably reduces probability of
29
30 survival (de Jong et al. 2014b).
31
32
33
34

35 **CONCLUSIONS AND OUTLOOK**

36
37 Although rarer than many other CNS cancers, retinoblastoma has offered
38
39 fundamental cancer knowledge, and clinicians and researchers have taken advantage
40
41 of its accessibility to carefully document and treat it using multiple modalities. We
42
43 envisage several areas for future developments to improve our understanding and
44
45 clinical management of this cancer.
46
47
48
49

50 **Trilateral retinoblastoma.** Our improving knowledge of the clinical behavior of
51
52 intracranial tumors in retinoblastoma has not been matched by our understanding of
53
54 their molecular features. It will be valuable to determine if there are molecular
55
56
57
58
59
60

1
2
3 characteristics of certain heritable retinoblastomas that might predispose to formation of
4
5 trilateral tumors. These might include *RB1* genotype, *DICER1* genotype, protein marker
6
7 expression, features on high resolution imaging, or others. Trilateral retinoblastoma
8
9 tumors (like their anatomical counterparts not associated with retinoblastoma) might
10
11 benefit from targeted therapy, and each could benefit from discoveries in the other in
12
13 this domain. The availability of mice that develop trilateral retinoblastoma-like tumors
14
15 makes preclinical studies technically feasible, but the low frequency of intracranial tumor
16
17 formation in these mice plus the need for histological diagnosis makes such studies
18
19 challenging.
20
21
22
23
24

25 ***MYCN* retinoblastoma.** The study of *MYCN* retinoblastoma can gain much from the
26
27 wealth of knowledge available for *MYCN* neuroblastoma (Huang and Weiss 2013).
28
29 Despite caveats (Wu et al. 2017), the potential for targeted agents borrowed from
30
31 neuroblastoma research to treat *MYCN* retinoblastoma is exciting. Currently, these
32
33 would only be useful for metastatic disease as the *MYCN* genotype is only determined
34
35 post-enucleation (recall that intraocular retinoblastoma is not biopsied due to risk of
36
37 tumor dissemination). But a promising new 'liquid biopsy' technique could change this,
38
39 as it allows for capture and molecular analysis of tumor DNA from the aqueous humor
40
41 of the eye, which can be safely removed with techniques that minimize risk of tumor
42
43 spread (Berry et al. 2017). This approach could potentially be used to identify *MYCN*
44
45 tumors *in situ*. Moreover, if distinguishing characteristics of *MYCN* tumors could be
46
47 discovered in OCT, fundus, ultrasound, or magnetic resonance imaging, or in circulating
48
49 tumor cells or DNA, targeting the primary tumor would also be possible. Large,
50
51 prospective studies will be needed to find these characteristics. Similarly, comparison of
52
53
54
55
56
57
58
59
60

1
2
3 the molecular features (genomic, proteomic, and signaling changes) of *MYCN*
4 retinoblastoma with *MYCN* neuroblastoma may reveal shared vulnerabilities or unique
5 characteristics.
6
7
8
9

10
11 Deciphering the cell of origin of *MYCN* retinoblastoma is likewise important. One
12 way to explore this would be to parallel the work that identified cone precursors as a
13 likely origin of at least some *RB1*^{-/-} retinoblastoma by knocking down *RB1* in dissociated
14 human fetal retinal cells and observing which cell types can proliferate (Xu et al. 2014).
15 A similar experiment, overexpressing *MYCN* instead of removing *RB1*, could perhaps
16 provide insight into retinal cells susceptible to proliferation after *MYCN* gain.
17
18
19
20
21
22
23
24
25

26 **Imaging.** Tumor imaging has revolutionized care of retinoblastoma, and could
27 perhaps be further applied to research on other CNS tumors. The powerful combination
28 of fundus imaging and OCT makes the prospect of xenografting other tumor types into
29 the eye an appealing one, especially for neural tumors where intravitreal or subretinal
30 injection would be more facile than intracranial xenografting. Although the intraocular
31 microenvironment differs from the brain, it offers similarities (neuronal and glial
32 neighboring cells, separation from the blood by a semi-permeable barrier) that
33 subcutaneous xenografts lack. Such paratopic xenografts could be easily followed using
34 the imaging modalities above, and will be an interesting area for further exploration.
35
36
37
38
39
40
41
42
43
44
45
46

47 Retinoblastoma may also learn from imaging in CNS tumors. Molecular imaging via
48 positron emission tomography (PET) or single photon emission computed tomography
49 (SPECT) is showing promise for brain tumors, especially using radiolabeled amino acid
50 tracers (Brindle et al. 2017). But the rare research on these imaging modalities in
51
52
53
54
55
56
57
58
59
60

1
2
3 retinoblastoma has shown little-to-no promise, offering no additional insight on tumor
4 features or response to treatment (Moll et al. 2004). Further research including novel
5 tracer development may be indicated. However, the need to keep radiation exposure
6 low for heritable retinoblastoma cases must also be considered.
7
8
9
10
11
12

13 Large imaging studies might also reveal other imaging biomarkers that could help
14 stratify retinoblastomas for improved prognostication and treatment decisions. Such
15 work could impact identification of both trilateral-predisposed and *MYCN*
16 retinoblastoma, as noted above. Further ability to look out for distinctive features in the
17 eyes of retinoblastoma patients will continue to improve the outlook for this visible CNS
18 tumor.
19
20
21
22
23
24
25
26
27

28 **ACKNOWLEDGEMENTS**

29
30 We thank Dr. Furqan Shaikh for comments on the draft manuscript. We thank Leslie
31 MacKeen, Dr. Cynthia Hawkins and Dr. Brenda L. Gallie for providing images for the
32 figures.
33
34
35
36
37

38 **CONFLICT OF INTEREST**

39
40 The authors have no conflicts of interest.
41
42

43 **ROLE OF AUTHORS**

44
45 Conceptualization: H.D., T.W.C.; Writing – Original Draft: H.D., T.W.C.; Writing –
46 Review & Editing: H.D., T.W.C.; Visualization: H.D., T.W.C.
47
48
49
50
51
52
53
54
55
56
57
58
59
60

REFERENCES

- Bader JL, Miller RW, Meadows AT, Zimmerman LE, Champion LA, Voute PA. 1980. Trilateral retinoblastoma. *Lancet* 2(8194):582-583.
- Bastawrous A. 2016. Increasing access to eye care ... there's an app for that. Peek: smartphone technology for eye health. *Int J Epidemiol* 45(4):1040-1043.
- Bastawrous A, Rono HK, Livingstone IA, Weiss HA, Jordan S, Kuper H, Burton MJ. 2015. Development and validation of a smartphone-based visual acuity test (Peek Acuity) for clinical practice and community-based fieldwork. *JAMA Ophthalmol* 133(8):930-937.
- Beck Popovic M, Balmer A, Maeder P, Braganca T, Munier FL. 2006. Benign pineal cysts in children with bilateral retinoblastoma: a new variant of trilateral retinoblastoma? *Pediatr Blood Cancer* 46(7):755-761.
- Benavente CA, Dyer MA. 2015. Genetics and epigenetics of human retinoblastoma. *Annu Rev Pathol* 10:547-562.
- Berry JL, Cobrinik D, Kim JW. 2016. Detection and intraretinal localization of an 'invisible' retinoblastoma using optical coherence tomography. *Ocul Oncol Pathol* 2(3):148-152.
- Berry JL, Xu L, Murphree A, et al. 2017. Potential of aqueous humor as a surrogate tumor biopsy for retinoblastoma. *JAMA Ophthalmol* 135(11):1221-1230.
- Bohringer HJ, Lankenau E, Stellmacher F, Reusche E, Huttmann G, Giese A. 2009. Imaging of human brain tumor tissue by near-infrared laser coherence tomography. *Acta Neurochir (Wien)* 151(5):507-517; discussion 517.
- Bowles E, Corson TW, Bayani J, Squire JA, Wong N, Lai PB, Gallie BL. 2007. Profiling genomic copy number changes in retinoblastoma beyond loss of *RB1*. *Genes Chromosomes Cancer* 46(2):118-129.
- Brennan RC, Federico S, Bradley C, Zhang J, Flores-Otero J, Wilson M, Stewart C, Zhu F, Guy K, Dyer MA. 2011. Targeting the p53 pathway in retinoblastoma with subconjunctival Nutlin-3a. *Cancer Res* 71(12):4205-4213.
- Brindle KM, Izquierdo-Garcia JL, Lewis DY, Mair RJ, Wright AJ. 2017. Brain tumor imaging. *J Clin Oncol* 35(21):2432-2438.
- Bullock JD, Campbell RJ, Waller RR. 1977. Calcification in retinoblastoma. *Invest Ophthalmol Vis Sci* 16(3):252-255.
- Cao C, Markovitz M, Ferenczy S, Shields CL. 2014. Hand-held spectral-domain optical coherence tomography of small macular retinoblastoma in infants before and after chemotherapy. *J Pediatr Ophthalmol Strabismus* 51(4):230-234.

- 1
2
3 Cebulla CM, Jockovich ME, Boutrid H, Pina Y, Ruggeri M, Jiao S, Bhattacharya SK,
4 Feuer WJ, Murray TG. 2008. Lack of effect of SU1498, an inhibitor of vascular
5 endothelial growth factor receptor-2, in a transgenic murine model of
6 retinoblastoma. *Open Ophthalmol J* 2:62-67.
7
8
9 Chan HS, DeBoer G, Thiessen JJ, Budning A, Kingston JE, O'Brien JM, Koren G,
10 Giesbrecht E, Haddad G, Verjee Z, Hungerford JL, Ling V, Gallie BL. 1996.
11 Combining cyclosporin with chemotherapy controls intraocular retinoblastoma
12 without requiring radiation. *Clin Cancer Res* 2(9):1499-1508.
13
14 Chantada G, Doz F, Antoneli CB, Grundy R, Clare Stannard FF, Dunkel IJ, Grabowski
15 E, Leal-Leal C, Rodriguez-Galindo C, Schvartzman E, Popovic MB, Kremens B,
16 Meadows AT, Zucker JM. 2006. A proposal for an international retinoblastoma
17 staging system. *Pediatr Blood Cancer* 47(6):801-805.
18
19
20 Conkrite K, Sundby M, Mukai S, Thomson JM, Mu D, Hammond SM, MacPherson D.
21 2011. miR-17~92 cooperates with RB pathway mutations to promote
22 retinoblastoma. *Genes Dev* 25(16):1734-1745.
23
24 Corson TW, Gallie BL. 2007. One hit, two hits, three hits, more? Genomic changes in
25 the development of retinoblastoma. *Genes Chromosomes Cancer* 46(7):617-634.
26
27
28 Corson TW, Samuels BC, Wenzel AA, Geary AJ, Riley AA, McCarthy BP, Hanenberg
29 H, Bailey BJ, Rogers PI, Pollok KE, Rajashekhar G, Territo PR. 2014.
30 Multimodality imaging methods for assessing retinoblastoma orthotopic xenograft
31 growth and development. *PLoS One* 9(6):e99036.
32
33
34 Dai S, Dimaras H, Heon E, Budning A, Doyle J, Halliday W, Drake J, Gallie BL, Chan
35 HS. 2008. Trilateral retinoblastoma with pituitary-hypothalamic dysfunction.
36 *Ophthalmic Genet* 29(3):120-125.
37
38 de Graaf P, Gorické S, Rodjan F, Galluzzi P, Maeder P, Castelijns JA, Brisse HJ,
39 European Retinoblastoma Imaging Collaboration. 2012. Guidelines for imaging
40 retinoblastoma: imaging principles and MRI standardization. *Pediatr Radiol*
41 42(1):2-14.
42
43
44 De Ioris MA, Valente P, Randisi F, Buzzonetti L, Carai A, Cozza R, Del Bufalo F,
45 Romano A, Angioni A, Cacchione A, Bernardi B, Mastronuzzi A. 2014. Baseline
46 central nervous system magnetic resonance imaging in early detection of
47 trilateral retinoblastoma: pitfalls in the diagnosis of pineal gland lesions.
48 *Anticancer Res* 34(12):7449-7454.
49
50
51 de Jong MC, de Graaf P, Noij DP, Gorické S, Maeder P, Galluzzi P, Brisse HJ, Moll AC,
52 Castelijns JA, European Retinoblastoma Imaging Collaboration. 2014a.
53 Diagnostic performance of magnetic resonance imaging and computed
54 tomography for advanced retinoblastoma: a systematic review and meta-
55 analysis. *Ophthalmology* 121(5):1109-1118.
56
57
58
59
60

- 1
2
3 de Jong MC, Kors WA, de Graaf P, Castelijns JA, Kivela T, Moll AC. 2014b. Trilateral
4 retinoblastoma: a systematic review and meta-analysis. *Lancet Oncol*
5 15(10):1157-1167.
6
7 de Jong MC, Kors WA, de Graaf P, Castelijns JA, Moll AC, Kivela T. 2015. The
8 incidence of trilateral retinoblastoma: a systematic review and meta-analysis. *Am*
9 *J Ophthalmol* 160(6):1116-1126 e1115.
10
11 de Jong MC, Moll AC, Goricke S, van der Valk P, Kors WA, Castelijns JA, de Graaf P.
12 2016. From a suspicious cystic pineal gland to pineoblastoma in a patient with
13 familial unilateral retinoblastoma. *Ophthalmic Genet* 37(1):116-118.
14
15 de Kock L, Sabbaghian N, Druker H, Weber E, Hamel N, Miller S, Choong CS, Gottardo
16 NG, Kees UR, Rednam SP, van Hest LP, Jongmans MC, Jhangiani S, Lupski
17 JR, Zacharin M, Bouron-Dal Soglio D, Huang A, Priest JR, Perry A, Mueller S,
18 Albrecht S, Malkin D, Grundy RG, Foulkes WD. 2014. Germ-line and somatic
19 *DICER1* mutations in pineoblastoma. *Acta Neuropathol* 128(4):583-595.
20
21
22
23 Dick FA, Rubin SM. 2013. Molecular mechanisms underlying RB protein function. *Nat*
24 *Rev Mol Cell Biol* 14(5):297-306.
25
26 Dimaras H, Corson TW. 2016. The molecular genetics of retinoblastoma. *Rev Cell Biol*
27 *Mol Med* 2:105-142.
28
29 Dimaras H, Corson TW, Cobrinik D, White A, Zhao J, Munier FL, Abramson DH, Shields
30 CL, Chantada GL, Njuguna F, Gallie BL. 2015. Retinoblastoma. *Nat Rev Dis*
31 *Primers* 1:15021.
32
33
34 Dimaras H, Dimba EA, Gallie BL. 2010a. Challenging the global retinoblastoma survival
35 disparity through a collaborative research effort. *Br J Ophthalmol* 94(11):1415-
36 1416.
37
38
39 Dimaras H, Heon E, Doyle J, Strahlendorf C, Paton KE, Halliday W, Babyn P, Gallie BL,
40 Chan HS. 2011. Multifaceted chemotherapy for trilateral retinoblastoma. *Arch*
41 *Ophthalmol* 129(3):362-365.
42
43 Dimaras H, Khetan V, Halliday W, Heon E, Chan HS, Gallie BL. 2009. Retinoma
44 underlying retinoblastoma revealed after tumor response to 1 cycle of
45 chemotherapy. *Arch Ophthalmol* 127(8):1066-1068.
46
47 Dimaras H, Khetan V, Halliday W, Orlic M, Prigoda NL, Piovesan B, Marrano P, Corson
48 TW, Eagle RC, Jr., Squire JA, Gallie BL. 2008. Loss of *RB1* induces non-
49 proliferative retinoma: increasing genomic instability correlates with progression
50 to retinoblastoma. *Hum Mol Genet* 17(10):1363-1372.
51
52
53 Dimaras H, Kimani K, Dimba EA, Gronsdahl P, White A, Chan HS, Gallie BL. 2012.
54 Retinoblastoma. *Lancet* 379(9824):1436-1446.
55
56
57
58
59
60

- 1
2
3 Dimaras H, Rushlow D, Halliday W, Doyle JJ, Babyn P, Abella EM, Williams J, Heon E,
4 Gallie BL, Chan HS. 2010b. Using *RB1* mutations to assess minimal residual
5 disease in metastatic retinoblastoma. *Transl Res* 156(2):91-97.
6
7
8 Do JL, Do B, Berry JL. 2017. Optical coherence tomography for diagnosis and
9 management of retinoblastoma. *Adv Ophthalmol Optom* 2(1):101-118.
10
11 Duffner PK, Cohen ME, Thomas PR, Lansky SB. 1985. The long-term effects of cranial
12 irradiation on the central nervous system. *Cancer* 56(7 Suppl):1841-1846.
13
14 Dunkel IJ, Jubran RF, Gururangan S, Chantada GL, Finlay JL, Goldman S, Khakoo Y,
15 O'Brien JM, Orjuela M, Rodriguez-Galindo C, Souweidane MM, Abramson DH.
16 2010. Trilateral retinoblastoma: potentially curable with intensive chemotherapy.
17 *Pediatr Blood Cancer* 54(3):384-387.
18
19
20 Dvorak L, Russell SR. 2011. Retinal drawing: a lost art of medicine. *Perm J* 15(3):74-75.
21
22 Eagle RC, Jr. 2009. High-risk features and tumor differentiation in retinoblastoma: a
23 retrospective histopathologic study. *Arch Pathol Lab Med* 133(8):1203-1209.
24
25 Eagle RC, Jr. 2013. The pathology of ocular cancer. *Eye* 27(2):128-136.
26
27 Evans L, Chen L, Milazzo G, Gherardi S, Perini G, Willmore E, Newell DR, Tweddle DA.
28 2015. SKP2 is a direct transcriptional target of MYCN and a potential therapeutic
29 target in neuroblastoma. *Cancer Lett* 363(1):37-45.
30
31
32 Ewens KG, Bhatti TR, Moran KA, Richards-Yutz J, Shields CL, Eagle RC, Ganguly A.
33 2017. Phosphorylation of pRb: mechanism for RB pathway inactivation in *MYCN*-
34 amplified retinoblastoma. *Cancer Med* 6(3):619-630.
35
36
37 Finger PT. 2009. The 7th Edition AJCC Staging System for Eye Cancer an international
38 language for ophthalmic oncology. *Arch Pathol Lab Med* 133(8):1197-1198.
39
40 Foster FS, Brown AS. 2012. Microultrasound and its application to longitudinal studies
41 of mouse eye development and disease. *Cold Spring Harb Protoc* 2012(4):494-
42 503.
43
44 Francis JH, Abramson DH, Gaillard MC, Marr BP, Beck-Popovic M, Munier FL. 2015.
45 The classification of vitreous seeds in retinoblastoma and response to intravitreal
46 melphalan. *Ophthalmology* 122(6):1173-1179.
47
48 Francis JH, Marr BP, Abramson DH. 2016. Classification of vitreous seeds in
49 retinoblastoma: Correlations with patient, tumor, and treatment characteristics.
50 *Ophthalmology* 123(7):1601-1605.
51
52
53 Friedman DN, Lis E, Sklar CA, Oeffinger KC, Reppucci M, Fleischut MH, Francis JH,
54 Marr B, Abramson DH, Dunkel IJ. 2014. Whole-body magnetic resonance
55
56
57
58
59
60

- 1
2
3 imaging (WB-MRI) as surveillance for subsequent malignancies in survivors of
4 hereditary retinoblastoma: a pilot study. *Pediatr Blood Cancer* 61(8):1440-1444.
5
6 Friend SH, Bernards R, Rogelj S, Weinberg RA, Rapaport JM, Albert DM, Dryja TP.
7 1986. A human DNA segment with properties of the gene that predisposes to
8 retinoblastoma and osteosarcoma. *Nature* 323(6089):643-646.
9
10 Fujimoto J, Swanson E. 2016. The development, commercialization, and impact of
11 optical coherence tomography. *Invest Ophthalmol Vis Sci* 57(9):OCT1-OCT13.
12
13 Fung YK, Murphree AL, T'Ang A, Qian J, Hinrichs SH, Benedict WF. 1987. Structural
14 evidence for the authenticity of the human retinoblastoma gene. *Science*
15 236(4809):1657-1661.
16
17 Gallie BL, Budning A, DeBoer G, Thiessen JJ, Koren G, Verjee Z, Ling V, Chan HS.
18 1996. Chemotherapy with focal therapy can cure intraocular retinoblastoma
19 without radiotherapy. *Arch Ophthalmol* 114(11):1321-1328.
20
21 Gallie BL, Ellsworth RM, Abramson DH, Phillips RA. 1982a. Retinoma: spontaneous
22 regression of retinoblastoma or benign manifestation of the mutation? *Br J*
23 *Cancer* 45(4):513-521.
24
25 Gallie BL, Mallipatna A, Finger P, Zhao J, Kivela T, Chantada G, Lau W, Ramirez-Ortiz
26 MA, Catala J, Yousef Y, Ushakova T, Yarovoy A, Wilson M, Khetan V, Walsh J,
27 Blair P, Renner L, Teekappanava N. 2016. International survey of staging for
28 retinoblastoma provides evidence for the 2016 8th Edition AJCC TNMH
29 retinoblastoma cancer staging. *Pediatr Blood Cancer* 63:S21-S21.
30
31 Gallie BL, Phillips RA, Ellsworth RM, Abramson DH. 1982b. Significance of retinoma
32 and phthisis bulbi for retinoblastoma. *Ophthalmology* 89(12):1393-1399.
33
34 Galluzzi P, de Jong MC, Sirin S, Maeder P, Piu P, Cerase A, Monti L, Brisse HJ,
35 Castelijns JA, de Graaf P, Goericke SL, European Retinoblastoma Imaging
36 Collaboration. 2016. MRI-based assessment of the pineal gland in a large
37 population of children aged 0-5 years and comparison with pineoblastoma: part I,
38 the solid gland. *Neuroradiology* 58(7):705-712.
39
40 Galluzzi P, Hadjistilianou T, Cerase A, De Francesco S, Toti P, Venturi C. 2009. Is CT
41 still useful in the study protocol of retinoblastoma? *AJNR Am J Neuroradiol*
42 30(9):1760-1765.
43
44 Gao SS, Jia Y, Zhang M, Su JP, Liu G, Hwang TS, Bailey ST, Huang D. 2016. Optical
45 coherence tomography angiography. *Invest Ophthalmol Vis Sci* 57(9):OCT27-36.
46
47 Giglio E, Sherman J. 1979. Ophthalmic ultrasound as a diagnostic tool. *J Am Optom*
48 *Assoc* 50(1):73-78.
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 Gilbert F, Balaban G, Breg WR, Gallie B, Reid T, Nichols W. 1981. Homogeneously
4 staining region in a retinoblastoma cell line: relevance to tumor initiation and
5 progression. *J Natl Cancer Inst* 67(2):301-306.
6
7 Gupta AK, Jones M, Prelog K, Bui J, Zhu J, Ng A, Dalla-Pozza L. 2016. Pineal cysts-A
8 benign association with familial retinoblastoma. *Pediatr Hematol Oncol*
9 33(6):408-414.
10
11 Hamel P, Heon E, Gallie BL, Budning AS. 2000. Focal therapy in the management of
12 retinoblastoma: when to start and when to stop. *J AAPOS* 4(6):334-337.
13
14 Hernandez JC, Brady LW, Shields CL, Shields JA, DePotter P. 1993. Conservative
15 treatment of retinoblastoma. The use of plaque brachytherapy. *Am J Clin Oncol*
16 16(5):397-401.
17
18 Hlavac M, Wirtz CR, Halatsch ME. 2017. Intraoperative magnetic resonance imaging.
19 *HNO* 65(1):25-29.
20
21 Huang M, Weiss WA. 2013. Neuroblastoma and *MYCN*. *Cold Spring Harb Perspect*
22 *Med* 3(10):a014415.
23
24 Jakobiec FA, Tso MO, Zimmerman LE, Danis P. 1977. Retinoblastoma and intracranial
25 malignancy. *Cancer* 39(5):2048-2058.
26
27 Ji X, Cheng L, Wei F, Li H, Wang M, Tian Y, Chen X, Wang Y, Wolf F, Li C, Huang Q.
28 2009. Noninvasive visualization of retinoblastoma growth and metastasis via
29 bioluminescence imaging. *Invest Ophthalmol Vis Sci* 50(12):5544-5551.
30
31 Kamihara J, Bourdeaut F, Foulkes WD, Molenaar JJ, Mosse YP, Nakagawara A,
32 Parareda A, Scollon SR, Schneider KW, Skalet AH, States LJ, Walsh MF, Diller
33 LR, Brodeur GM. 2017. Retinoblastoma and neuroblastoma predisposition and
34 surveillance. *Clin Cancer Res* 23(13):e98-e106.
35
36 Karatza EC, Shields CL, Flanders AE, Gonzalez ME, Shields JA. 2006. Pineal cyst
37 simulating pinealoblastoma in 11 children with retinoblastoma. *Arch Ophthalmol*
38 124(4):595-597.
39
40 Karcioglu ZA. 2002. Fine needle aspiration biopsy (FNAB) for retinoblastoma. *Retina*
41 22(6):707-710.
42
43 Kashyap S, Meel R, Pushker N, Sen S, Bakhshi S, Bajaj MS, Chawla B, Sethi S, Ghose
44 S, Chandra M. 2011. Phthisis bulbi in retinoblastoma. *Clin Exp Ophthalmol*
45 39(2):105-110.
46
47 Kendall CJ, Prager TC, Cheng H, Gombos D, Tang RA, Schiffman JS. 2015. Diagnostic
48 ophthalmic ultrasound for radiologists. *Neuroimaging Clin N Am* 25(3):327-365.
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 Kenyan National Retinoblastoma Strategy Group. 2014. Retinoblastoma Best Practice
4 Guidelines.
5
- 6 Kim JW, Ngai LK, Sadda S, Murakami Y, Lee DK, Murphree AL. 2014. Retcam
7 fluorescein angiography findings in eyes with advanced retinoblastoma. *Br J*
8 *Ophthalmol* 98(12):1666-1671.
9
- 10 Kivela T. 1999. Trilateral retinoblastoma: a meta-analysis of hereditary retinoblastoma
11 associated with primary ectopic intracranial retinoblastoma. *J Clin Oncol*
12 17(6):1829-1837.
13
14
- 15 Knudson AG, Jr. 1971. Mutation and cancer: statistical study of retinoblastoma. *Proc*
16 *Natl Acad Sci U S A* 68(4):820-823.
17
- 18 Kooi IE, Mol BM, Massink MP, Ameziane N, Meijers-Heijboer H, Dommering CJ, van Mil
19 SE, de Vries Y, van der Hout AH, Kaspers GJ, Moll AC, Te Riele H, Cloos J,
20 Dorsman JC. 2016a. Somatic genomic alterations in retinoblastoma beyond *RB1*
21 are rare and limited to copy number changes. *Sci Rep* 6:25264.
22
23
- 24 Kooi IE, Mol BM, Massink MP, de Jong MC, de Graaf P, van der Valk P, Meijers-
25 Heijboer H, Kaspers GJ, Moll AC, Te Riele H, Cloos J, Dorsman JC. 2016b. A
26 meta-analysis of retinoblastoma copy numbers refines the list of possible driver
27 genes involved in tumor progression. *PLoS One* 11(4):e0153323.
28
29
- 30 Kooi IE, Mol BM, Moll AC, van der Valk P, de Jong MC, de Graaf P, van Mil SE,
31 Schouten-van Meeteren AY, Meijers-Heijboer H, Kaspers GL, Te Riele H, Cloos
32 J, Dorsman JC. 2015. Loss of photoreceptoriness and gain of genomic alterations
33 in retinoblastoma reveal tumor progression. *EBioMedicine* 2(7):660-670.
34
35
- 36 Lambertz I, Nittner D, Mestdagh P, Denecker G, Vandesompele J, Dyer MA, Marine JC.
37 2010. Monoallelic but not biallelic loss of *Dicer1* promotes tumorigenesis in vivo.
38 *Cell Death Differ* 17(4):633-641.
39
- 40 Larina IV, Syed SH, Sudheendran N, Overbeek PA, Dickinson ME, Larin KV. 2012.
41 Optical coherence tomography for live phenotypic analysis of embryonic ocular
42 structures in mouse models. *J Biomed Optics* 17(8):081410-081411.
43
- 44 Laurent VE, Otero LL, Vazquez V, Camarero S, Gabri MR, Labraga M, De Davila MT,
45 Chantada GL, Alonso DF. 2010. Optimization of molecular detection of GD2
46 synthase mRNA in retinoblastoma. *Mol Med Rep* 3(2):253-259.
47
48
- 49 Laurent VE, Sampor C, Solernou V, Rossi J, Gabri M, Eandi-Eberle S, de Davila MT,
50 Alonso DF, Chantada GL. 2013. Detection of minimally disseminated disease in
51 the cerebrospinal fluid of children with high-risk retinoblastoma by reverse
52 transcriptase-polymerase chain reaction for GD2 synthase mRNA. *Eur J Cancer*
53 49(13):2892-2899.
54
55
56
57
58
59
60

- 1
2
3 Laurie NA, Gray JK, Zhang J, Leggas M, Relling M, Egorin M, Stewart C, Dyer MA.
4 2005. Topotecan combination chemotherapy in two new rodent models of
5 retinoblastoma. *Clin Cancer Res* 11(20):7569-7578.
6
7
8 Laws Jr. ER, Curran Jr. WJ, Bondy ML, Brat DJ, Brem H, Chang SM, Colen RR, Lopes
9 MB, Louis DN, Prados MD, Schiff D, Vallerand TM, Wen PY, Werner-Wasik M.
10 2017. Brain and Spinal Cord. In: Amin MB, Edge S, Greene F, Byrd DR,
11 Brookland RK, Washington MK, Gershenwald JE, Compton CC, Hess KR,
12 Sullivan DC, Jessup JM, Brierley JD, Gaspar LE, Schilsky RL, Balch CM,
13 Winchester DP, Asare EA, Madera M, Gress DM, Meyer LR, editors. *AJCC*
14 *Cancer Staging Manual* (8th ed). New York: Springer International Publishing.
15
16
17 Lee WH, Bookstein R, Hong F, Young LJ, Shew JY, Lee EY. 1987. Human
18 retinoblastoma susceptibility gene: cloning, identification, and sequence. *Science*
19 235(4794):1394-1399.
20
21
22 Lemaitre S, Poyer F, Marco S, Freneaux P, Doz F, Aerts I, Desjardins L, Cassoux N,
23 Thomas CD. 2017. Looking for the most suitable orthotopic retinoblastoma
24 mouse model in order to characterize the tumoral development. *Invest*
25 *Ophthalmol Vis Sci* 58(7):3055-3064.
26
27
28 Levy J, Frenkel S, Baras M, Neufeld M, Pe'er J. 2011. Calcification in retinoblastoma:
29 histopathologic findings and statistical analysis of 302 cases. *Br J Ophthalmol*
30 95(8):1145-1150.
31
32
33 Li MH, Bouffet E, Hawkins CE, Squire JA, Huang A. 2005. Molecular genetics of
34 supratentorial primitive neuroectodermal tumors and pineoblastoma. *Neurosurg*
35 *Focus* 19(5):E3.
36
37
38 Lodhia V, Karanja S, Lees S, Bastawrous A. 2016. Acceptability, usability, and views on
39 deployment of Peek, a mobile phone mhealth intervention for eye care in Kenya:
40 Qualitative study. *JMIR Mhealth Uhealth* 4(2):e30.
41
42
43 Lohmann DR, Brandt B, Hopping W, Passarge E, Horsthemke B. 1994. Distinct *RB1*
44 gene mutations with low penetrance in hereditary retinoblastoma. *Hum Genet*
45 94(4):349-354.
46
47
48 Lohmann DR, Gallie BL. 2004. Retinoblastoma: revisiting the model prototype of
49 inherited cancer. *Am J Med Genet* 129C(1):23-28.
50
51
52 MacCarthy A, Bayne AM, Brownbill PA, Bunch KJ, Diggens NL, Draper GJ, Hawkins
53 MM, Jenkinson HC, Kingston JE, Stiller CA, Vincent TJ, Murphy MF. 2013.
54 Second and subsequent tumours among 1927 retinoblastoma patients
55 diagnosed in Britain 1951-2004. *Br J Cancer* 108(12):2455-2463.
56
57
58
59
60 Mallipatna AC, Gallie BL, Chevez-Barrios P, Lumbroso-Le Rouic L, Chantada GL,
61 Brisse HJ, Doz F, Munier FL, Albert DM, Català-Mora J, Desjardins LG, Suzuki
62 S, Carroll WL, Coupland SE, Finger PT. 2017. Retinoblastoma. In: Amin MB,

1
2
3 Edge S, Greene F, Byrd DR, Brookland RK, Washington MK, Gershenwald JE,
4 Compton CC, Hess KR, Sullivan DC, Jessup JM, Brierley JD, Gaspar LE,
5 Schilsky RL, Balch CM, Winchester DP, Asare EA, Madera M, Gress DM, Meyer
6 LR, editors. *AJCC Cancer Staging Manual* (8th ed). New York: Springer
7 International Publishing.
8

9
10 Marcus DM, Carpenter JL, O'Brien JM, Kivela T, Brauner E, Tarkkanen A, Virtanen I,
11 Albert DM. 1991. Primitive neuroectodermal tumor of the midbrain in a murine
12 model of retinoblastoma. *Invest Ophthalmol Vis Sci* 32(2):293-301.
13

14 Marcus DM, Lasudry JG, Carpenter JL, Windle J, Howes KA, al-Ubaidi MR, Baehr W,
15 Overbeek PA, Font RL, Albert DM. 1996. Trilateral tumors in four different lines
16 of transgenic mice expressing SV40 T-antigen. *Invest Ophthalmol Vis Sci*
17 37(2):392-396.
18

19
20 Mashayekhi A, Shields CL, Eagle RC, Jr., Shields JA. 2005. Cavitory changes in
21 retinoblastoma: relationship to chemoresistance. *Ophthalmology* 112(6):1145-
22 1150.
23

24 Materin MA, Kuzmik GA, Jubinsky PT, Minja FJ, Asnes JD, Bulsara KR. 2012.
25 Verification of supraselective drug delivery for retinoblastoma using intra-arterial
26 gadolinium. *BMJ Case Rep* 2012.
27

28
29 McEvoy J, Flores-Otero J, Zhang J, Nemeth K, Brennan R, Bradley C, Krafcik F,
30 Rodriguez-Galindo C, Wilson M, Xiong S, Lozano G, Sage J, Fu L, Louhibi L,
31 Trimarchi J, Pani A, Smeyne R, Johnson D, Dyer MA. 2011. Coexpression of
32 normally incompatible developmental pathways in retinoblastoma genesis.
33 *Cancer Cell* 20(2):260-275.
34

35
36 McEvoy J, Nagahawatte P, Finkelstein D, Richards-Yutz J, Valentine M, Ma J,
37 Mullighan C, Song G, Chen X, Wilson M, Brennan R, Pounds S, Becksfort J,
38 Huether R, Lu C, Fulton RS, Fulton LL, Hong X, Dooling DJ, Ochoa K, Mardis
39 ER, Wilson RK, Easton J, Zhang J, Downing JR, Ganguly A, Dyer MA. 2014.
40 *RB1* gene inactivation by chromothripsis in human retinoblastoma. *Oncotarget*
41 5(2):438-450.
42

43
44 Mendoza PR, Specht CS, Hubbard GB, Wells JR, Lynn MJ, Zhang Q, Kong J,
45 Grossniklaus HE. 2015. Histopathologic grading of anaplasia in retinoblastoma.
46 *Am J Ophthalmol* 159(4):764-776.
47

48 Ministry of Health Kenya. 2010. *Mother & Child Health Booklet*.
49

50
51 Moll AC, Hoekstra OS, Imhof SM, Comans EF, Schouten-van Meeteren AY, van der
52 Valk P, Boers M. 2004. Fluorine-18 fluorodeoxyglucose positron emission
53 tomography (PET) to detect vital retinoblastoma in the eye: preliminary
54 experience. *Ophthalmic Genet* 25(1):31-35.
55
56
57
58

- 1
2
3 Morjaria P, Bastawrous A, Murthy GVS, Evans J, Gilbert C. 2017. Effectiveness of a
4 novel mobile health education intervention (Peek) on spectacle wear among
5 children in India: study protocol for a randomized controlled trial. *Trials* 18(1):168.
6
7 Mrochuk J. 1990. Introduction to diagnostic ophthalmic ultrasound for nurses in
8 ophthalmology. *J Ophthalmic Nurs Technol* 9(6):234-239.
9
10 Mulhern RK, Reddick WE, Palmer SL, Glass JO, Elkin TD, Kun LE, Taylor J, Langston
11 J, Gajjar A. 1999. Neurocognitive deficits in medulloblastoma survivors and white
12 matter loss. *Ann Neurol* 46(6):834-841.
13
14 Munier FL. 2014. Classification and management of seeds in retinoblastoma. Ellsworth
15 Lecture Ghent August 24th 2013. *Ophthalmic Genet* 35(4):193-207.
16
17 Munier FL, Gaillard MC, Balmer A, Soliman S, Podilsky G, Moulin AP, Beck-Popovic M.
18 2012a. Intravitreal chemotherapy for vitreous disease in retinoblastoma revisited:
19 from prohibition to conditional indications. *Br J Ophthalmol* 96(8):1078-1083.
20
21 Munier FL, Soliman S, Moulin AP, Gaillard MC, Balmer A, Beck-Popovic M. 2012b.
22 Profiling safety of intravitreal injections for retinoblastoma using an anti-reflux
23 procedure and sterilisation of the needle track. *Br J Ophthalmol* 96(8):1084-1087.
24
25 Murphree AL. 2005. Intraocular retinoblastoma: the case for a new group classification.
26 *Ophthalmol Clin North Am* 18(1):41-53, viii.
27
28 National Retinoblastoma Strategy. 2009. National Retinoblastoma Strategy Canadian
29 Guidelines for Care: Strategie therapeutique du retinoblastome guide clinique
30 canadien. *Can J Ophthalmol* 44 Suppl 2:S1-88.
31
32 Nemeth KM, Federico S, Carcaboso AM, Shen Y, Schaiquevich P, Zhang J, Egorin M,
33 Stewart C, Dyer MA. 2011. Subconjunctival carboplatin and systemic topotecan
34 treatment in preclinical models of retinoblastoma. *Cancer* 117(2):421-434.
35
36 Novetsky DE, Abramson DH, Kim JW, Dunkel IJ. 2009. Published international
37 classification of retinoblastoma (ICRB) definitions contain inconsistencies--an
38 analysis of impact. *Ophthalmic Genet* 30(1):40-44.
39
40 Novotny A, Krasny J. 1990. [Diagnosis of retinoblastoma using ultrasound]. *Cas Lek*
41 *Cesk* 129(12):364-365.
42
43 O'Brien JM, Marcus DM, Bernards R, Carpenter JL, Windle JJ, Mellon P, Albert DM.
44 1990. A transgenic mouse model for trilateral retinoblastoma. *Arch Ophthalmol*
45 108(8):1145-1151.
46
47 O'Hare M, Shadmand M, Sulaiman RS, Sishtla K, Sakisaka T, Corson TW. 2016. *Kif14*
48 overexpression accelerates murine retinoblastoma development. *Int J Cancer*
49 139(8):1752-1758.
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 Pavlin CJ, McWhae JA, McGowan HD, Foster FS. 1992. Ultrasound biomicroscopy of
4 anterior segment tumors. *Ophthalmology* 99(8):1220-1228.
5
6 Pavlin CJ, Sherar MD, Foster FS. 1990. Subsurface ultrasound microscopic imaging of
7 the intact eye. *Ophthalmology* 97(2):244-250.
8
9
10 Racher H, Soliman S, Argiropoulos B, Chan HS, Gallie BL, Perrier R, Matevski D,
11 Rushlow D, Piovesan B, Shaikh F, MacDonald H, Corson TW. 2016. Molecular
12 analysis distinguishes metastatic disease from second cancers in patients with
13 retinoblastoma. *Cancer Genet* 209(7-8):359-363.
14
15 Razek AA, Elkhamary S. 2011. MRI of retinoblastoma. *Br J Radiol* 84(1005):775-784.
16
17 Reese AB, Ellsworth RM. 1963. The evaluation and current concept of retinoblastoma
18 therapy. *Trans Am Acad Ophthalmol Otolaryngol* 67:164-172.
19
20
21 Reminick LR, Finger PT, Ritch R, Weiss S, Ishikawa H. 1998. Ultrasound biomicroscopy
22 in the diagnosis and management of anterior segment tumors. *J Am Optom*
23 *Assoc* 69(9):575-582.
24
25
26 Rodjan F, de Graaf P, van der Valk P, Hadjistilianou T, Cerase A, Toti P, de Jong MC,
27 Moll AC, Castelijns JA, Galluzzi P, European Retinoblastoma Imaging
28 Collaboration. 2015. Detection of calcifications in retinoblastoma using gradient-
29 echo MR imaging sequences: comparative study between in vivo MR imaging
30 and ex vivo high-resolution CT. *AJNR Am J Neuroradiol* 36(2):355-360.
31
32 Romanowska Dixon B, Morawski K. 2017. Usefulness of Ret-Cam imaging in diagnosis,
33 treatment and monitoring of retinoblastoma. *Acta Ophthalmol* 95:10.1111/j.1755-
34 3768.2017.1110S1079.
35
36
37 Rootman DB, Gonzalez E, Mallapatna A, Vandenhoven C, Hampton L, Dimaras H, Chan
38 HS, Gallie BL, Heon E. 2013. Hand-held high-resolution spectral domain optical
39 coherence tomography in retinoblastoma: clinical and morphologic
40 considerations. *Br J Ophthalmol* 97(1):59-65.
41
42
43 Ruggeri M, Tsechpenakis G, Jiao S, Jockovich ME, Cebulla C, Hernandez E, Murray
44 TG, Puliafito CA. 2009. Retinal tumor imaging and volume quantification in
45 mouse model using spectral-domain optical coherence tomography. *Opt Express*
46 17(5):4074-4083.
47
48 Ruggeri M, Wehbe H, Jiao S, Gregori G, Jockovich ME, Hackam A, Duan Y, Puliafito
49 CA. 2007. In vivo three-dimensional high-resolution imaging of rodent retina with
50 spectral-domain optical coherence tomography. *Invest Ophthalmol Vis Sci*
51 48(4):1808-1814.
52
53
54 Ruiz-Perez MV, Henley AB, Arsenian-Henriksson M. 2017. The MYCN protein in health
55 and disease. *Genes (Basel)* 8(4).
56
57
58
59
60

- 1
2
3 Rushlow DE, Mol BM, Kennett JY, Yee S, Pajovic S, Theriault BL, Prigoda-Lee NL,
4 Spencer C, Dimaras H, Corson TW, Pang R, Massey C, Godbout R, Jiang Z,
5 Zacksenhaus E, Paton K, Moll AC, Houdayer C, Raizis A, Halliday W, Lam WL,
6 Boutros PC, Lohmann D, Dorsman JC, Gallie BL. 2013. Characterisation of
7 retinoblastomas without *RB1* mutations: genomic, gene expression, and clinical
8 studies. *Lancet Oncol* 14(4):327-334.
9
10
11 Samara WA, Pointdujour-Lim R, Say EA, Shields CL. 2015. Foveal microanatomy
12 documented by SD-OCT following treatment of advanced retinoblastoma. *J*
13 *AAPOS* 19(4):368-372.
14
15 Shields CL, Mashayekhi A, Au AK, Czyn C, Leahey A, Meadows AT, Shields JA. 2006.
16 The International Classification of Retinoblastoma predicts chemoreduction
17 success. *Ophthalmology* 113(12):2276-2280.
18
19
20 Shields CL, Materin MA, Shields JA. 2005. Restoration of foveal anatomy and function
21 following chemoreduction for bilateral advanced retinoblastoma with total retinal
22 detachment. *Arch Ophthalmol* 123(11):1610-1612.
23
24 Shields CL, Meadows AT, Shields JA, Carvalho C, Smith AF. 2001. Chemoreduction for
25 retinoblastoma may prevent intracranial neuroblastic malignancy (trilateral
26 retinoblastoma). *Arch Ophthalmol* 119(9):1269-1272.
27
28
29 Singh U, Malik MA, Goswami S, Shukla S, Kaur J. 2016. Epigenetic regulation of
30 human retinoblastoma. *Tumour Biol* 37(11):14427-14441.
31
32 Sirin S, de Jong MC, Galluzzi P, Maeder P, Brisse HJ, Castelijns JA, de Graaf P,
33 Goericke SL, European Retinoblastoma Imaging Collaboration. 2016. MRI-based
34 assessment of the pineal gland in a large population of children aged 0-5 years
35 and comparison with pineoblastoma: part II, the cystic gland. *Neuroradiology*
36 58(7):713-721.
37
38
39 Soliman SE, Dimaras H, Khetan V, Gardiner JA, Chan HS, Heon E, Gallie BL. 2016.
40 Prenatal versus postnatal screening for familial retinoblastoma. *Ophthalmology*
41 123(12):2610-2617.
42
43 Soliman SE, Racher H, Zhang C, MacDonald H, Gallie BL. 2017a. Genetics and
44 molecular diagnostics in retinoblastoma--an update. *Asia Pac J Ophthalmol*
45 6(2):197-207.
46
47 Soliman SE, VandenHoven C, MacKeen LD, Heon E, Gallie BL. 2017b. Optical
48 coherence tomography-guided decisions in retinoblastoma management.
49 *Ophthalmology* 124(6):859-872.
50
51
52 Sulaiman RS, Quigley J, Qi X, O'Hare MN, Grant MB, Boulton ME, Corson TW. 2015. A
53 simple optical coherence tomography quantification method for choroidal
54 neovascularization. *J Ocul Pharmacol Ther* 31(8):447-454.
55
56
57
58
59
60

- 1
2
3 Temming P, Arendt M, Viehmann A, Eisele L, Le Guin CH, Schundeln MM, Biewald E,
4 Mausert J, Wieland R, Bornfeld N, Sauerwein W, Eggert A, Lohmann DR, Jockel
5 KH. 2016. How eye-preserving therapy affects long-term overall survival in
6 heritable retinoblastoma survivors. *J Clin Oncol* 34(26):3183-3188.
7
8
9 Theriault BL, Dimaras H, Gallie BL, Corson TW. 2014. The genomic landscape of
10 retinoblastoma: a review. *Clin Experiment Ophthalmol* 42(1):33-52.
11
12 Torbidoni AV, Laurent VE, Sampor C, Ottaviani D, Vazquez V, Gabri MR, Rossi J, de
13 Davila MT, Alonso C, Alonso DF, Chantada GL. 2015. Association of cone-rod
14 homeobox transcription factor messenger RNA with pediatric metastatic
15 retinoblastoma. *JAMA Ophthalmol* 133(7):805-812.
16
17 Tschulakow AV, Schraermeyer U, Rodemann HP, Julien-Schraermeyer S. 2016.
18 Establishment of a novel retinoblastoma (Rb) nude mouse model by intravitreal
19 injection of human Rb Y79 cells - comparison of in vivo analysis versus
20 histological follow up. *Biol Open* 5(11):1625-1630.
21
22
23 Tso MO. 1980. Clues to the cells of origin in retinoblastoma. *Int Ophthalmol Clin*
24 20(2):191-210.
25
26 Valdes PA, Roberts DW, Lu FK, Golby A. 2016. Optical technologies for intraoperative
27 neurosurgical guidance. *Neurosurg Focus* 40(3):E8.
28
29
30 Vasquez LM, Giuliani GP, Halliday W, Pavlin CJ, Gallie BL, Heon E. 2011. Ultrasound
31 biomicroscopy in the management of retinoblastoma. *Eye* 25(2):141-147.
32
33 Velez-Cruz R, Johnson DG. 2017. The retinoblastoma (RB) tumor suppressor: Pushing
34 back against genome instability on multiple fronts. *Int J Mol Sci* 18(8), 1776.
35
36
37 Vuong B, Skowron P, Kiehl TR, Kyan M, Garzia L, Sun C, Taylor MD, Yang VX. 2015.
38 Measuring the optical characteristics of medulloblastoma with optical coherence
39 tomography. *Biomed Opt Express* 6(4):1487-1501.
40
41 Weiss WA, Aldape K, Mohapatra G, Feuerstein BG, Bishop JM. 1997. Targeted
42 expression of *MYCN* causes neuroblastoma in transgenic mice. *EMBO J*
43 16(11):2985-2995.
44
45 Wenzel AA, O'Hare MN, Shadmard M, Corson TW. 2015. Optical coherence
46 tomography enables imaging of tumor initiation in the TAg-RB mouse model of
47 retinoblastoma. *Mol Vis* 21:515-522.
48
49
50 Williams BO, Remington L, Albert DM, Mukai S, Bronson RT, Jacks T. 1994.
51 Cooperative tumorigenic effects of germline mutations in Rb and p53. *Nat Genet*
52 7(4):480-484.
53
54
55 Wilson RS. 1975. Retinal drawing chart. *Ophthalmic Surg* 6(1):17-21.
56
57
58
59
60

- 1
2
3 Wippold FJ, 2nd, Perry A. 2006. Neuropathology for the neuroradiologist: rosettes and
4 pseudorosettes. *AJNR Am J Neuroradiol* 27(3):488-492.
5
6 Wu N, Jia D, Bates B, Basom R, Eberhart CG, MacPherson D. 2017. A mouse model of
7 *MYCN*-driven retinoblastoma reveals *MYCN*-independent tumor reemergence. *J*
8 *Clin Invest* 127(3):888-898.
9
10 Xu XL, Singh HP, Wang L, Qi DL, Poulos BK, Abramson DH, Jhanwar SC, Cobrinik D.
11 2014. Rb suppresses human cone-precursor-derived retinoblastoma tumours.
12 *Nature* 514(7522):385-388.
13
14 Yousef YA, Shroff M, Halliday W, Gallie BL, Heon E. 2012. Detection of optic nerve
15 disease in retinoblastoma by use of spectral domain optical coherence
16 tomography. *J AAPOS* 16(5):481-483.
17
18 Yousef YA, Soliman SE, Astudillo PP, Durairaj P, Dimaras H, Chan HS, Heon E, Gallie
19 BL, Shaikh F. 2016. Intra-arterial chemotherapy for retinoblastoma: a systematic
20 review. *JAMA Ophthalmol* 134(5):584-591.
21
22 Zhang J, Benavente CA, McEvoy J, Flores-Otero J, Ding L, Chen X, Ulyanov A, Wu G,
23 Wilson M, Wang J, Brennan R, Rusch M, Manning AL, Ma J, Easton J, Shurtleff
24 S, Mullighan C, Pounds S, Mukatira S, Gupta P, Neale G, Zhao D, Lu C, Fulton
25 RS, Fulton LL, Hong X, Dooling DJ, Ochoa K, Naeve C, Dyson NJ, Mardis ER,
26 Bahrami A, Ellison D, Wilson RK, Downing JR, Dyer MA. 2012. A novel
27 retinoblastoma therapy from genomic and epigenetic analyses. *Nature*
28 481(7381):329-334.
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

FIGURE LEGENDS

Fig. 1. Clinical features of retinoblastoma. (a) External RetcamTM image of retinoblastoma; calcified tumor is visible through the pupil as leukocoria. (b) RetcamTM fundus image revealing two tumors (arrowheads), * = optic nerve head. (c) Gross pathology of an enucleated eye. A large, calcified tumor is apparent on the left side of the globe (arrowhead). (d) Pupillary-optic nerve section of an eye enucleated for retinoblastoma as primary treatment. (e) Homer Wright rosettes (arrowhead) and packed cells; (f) Viable collars of cells around blood vessels, and abundant necroses between them; (g) Area of retinoma, with fleurettes (arrowhead). Scale bars = 100 μ m.

Fig. 2. Retinoblastoma genetics. The cancer can initiate with a germline *RB1* mutation followed by a single somatic hit, or with two somatic mutations (M1 and M2). Loss of *RB1* leads to the benign retinoma; further mutations (M3 to Mn) are required for malignancy. Retinoblastoma can also initiate by amplification of *MYCN*, with other genomic changes as yet unknown.

Fig. 3. Retinoblastoma imaging. (a-b) RetcamTM (a) image of an eye reveals two large tumors, and ultrasound image (b) allows measurement of tumor height (yellow and green lines). (c) Axial T1 MRI post-gadolinium reveals tumor at back of eye (arrowhead). (d-f) Imaging of the eye of an infant with heritable retinoblastoma by RetcamTM (d) shows no visible tumor. OCT scan line shown in green/red. OCT imaging (e, en face; f, transverse section) reveals small tumor appearing to arise out of the inner nuclear layer of the retina (arrowhead). (g) Fundus photo (top) and OCT image (bottom) show a retinoblastoma-like tumor (arrowheads) arising in the TAG-RB mouse model. OCT scan line shown in red. Scale bars = 100 μ m.

1
2
3 Fig. 4. *MYCN* retinoblastoma. (a) Tumor appears retinoblastoma-like on fundus
4 image. (b) Ultrasound reveals characteristic calcification. (c) Histopathology of tumor in
5 enucleated eye reveals round nuclei with prominent large multiple nucleoli; contrast with
6 *RB1*^{-/-} retinoblastoma in Fig. 1e. Adapted with permission from (Rushlow et al. 2013).
7
8
9
10
11
12

13 Fig. 5. Trilateral retinoblastoma. (a) Sagittal T1-weighted and (b) coronal T2-
14 weighted fluid-attenuated inversion recovery (FLAIR) contrast MRI reveals suprasellar
15 mass in a patient who also has bilateral retinoblastoma. (c) Histology of this mass
16 reveals abundant Flexner-Wintersteiner and Homer Wright rosettes. Scale bar = 25 μm.
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Fig. 1. Clinical features of retinoblastoma. (a) External RetcamTM image of retinoblastoma; calcified tumor is visible through the pupil as leukocoria. (b) RetcamTM fundus image revealing two tumors (arrowheads), * = optic nerve head. (c) Gross pathology of an enucleated eye. A large, calcified tumor is apparent on the left side of the globe (arrowhead). (d) Pupillary-optic nerve section of an eye enucleated for retinoblastoma as primary treatment. (e) Homer Wright rosettes (arrowhead) and packed cells; (f) Viable collars of cells around blood vessels, and abundant necroses between them; (g) Area of retinoma, with fleurettes (arrowhead). Scale bars = 100 μ m.

242x136mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Fig. 2. Retinoblastoma genetics. The cancer can initiate with a germline *RB1* mutation followed by a single somatic hit, or with two somatic mutations (M1 and M2). Loss of *RB1* leads to the benign retinoma; further mutations (M3 to Mn) are required for malignancy. Retinoblastoma can also initiate by amplification of *MYCN*, with other genomic changes as yet unknown.

167x62mm (300 x 300 DPI)




Fig. 3. Retinoblastoma imaging. (a-b) RetacamTM (a) image of an eye reveals two large tumors, and ultrasound image (b) allows measurement of tumor height (yellow and green lines). (c) Axial T1 MRI post-gadolinium reveals tumor at back of eye (arrowhead). (d-f) Imaging of the eye of an infant with heritable retinoblastoma by RetacamTM (d) shows no visible tumor. OCT scan line shown in green/red. OCT imaging (e, en face; f, transverse section) reveals small tumor appearing to arise out of the inner nuclear layer of the retina (arrowhead). (g) Fundus photo (top) and OCT image (bottom) show a retinoblastoma-like tumor (arrowheads) arising in the TAG-RB mouse model. OCT scan line shown in red. Scale bars = 100 μ m.

171x82mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Fig. 4. MYCN retinoblastoma. (a) Tumor appears retinoblastoma-like on fundus image. (b) Ultrasound reveals characteristic calcification. (c) Histopathology of tumor in enucleated eye reveals round nuclei with prominent large multiple nucleoli; contrast with RB1-/- retinoblastoma in Fig. 1e. Adapted with permission from Rushlow et al. 2013.

81x218mm (300 x 300 DPI)





Fig. 5. Trilateral retinoblastoma. (a) Sagittal T1-weighted and (b) coronal T2-weighted fluid-attenuated inversion recovery (FLAIR) contrast MRI reveals suprasellar mass in a patient who also has bilateral retinoblastoma. (c) Histology of this mass reveals abundant Flexner-Wintersteiner rosettes. Scale bar = 25 μm .

81x28mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Retinoblastoma is a uniquely accessible CNS tumor. Imaging techniques for this cancer, the biology of its MYCN-driven form, and its "trilateral," intracranial manifestation provide interesting contrasts and parallels with other CNS malignancies.

103x78mm (150 x 150 DPI)

1
2
3 Retinoblastoma is a uniquely accessible CNS tumor. Imaging techniques for this
4
5 cancer, the biology of its *MYCN*-driven form, and its “trilateral,” intracranial
6
7 manifestation provide interesting contrasts and parallels with other CNS malignancies.
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For Peer Review